Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Halozyme Therapeutics, Inc. (HALO)
USD68.55
-0.02 (-0.03%)
US NASDAQ Healthcare Biotechnology
Address
11388 Sorrento Valley Road 92121
San Diego, CA, US
San Diego, CA, US
CEO
Helen I. Torley
Website
halozyme.com
IPO
2004-03-16
CIK 1159036 ISIN US40637H1095
Also trades on
London Stock Exchange · 0J2O.L (USD)
NASDAQ Global Select · HALO (USD)
Description
Halozyme Therapeutics, Inc. is a biopharmaceutical company headquartered in San Diego, California, with operations spanning the United States, Switzerland, Ireland, Belgium, Japan, and other international markets. At its core is the proprietary ENHANZE drug delivery platform, which utilizes a patented recombinant human hyaluronidase enzyme (rHuPH20). This innovative technology significantly enhances the subcutaneous (under-the-skin) administration of a diverse range of injectable medicines. This includes complex biologics such as monoclonal antibodies, various other therapeutic molecules, smaller drug compounds, and even fluids. The company's leading product, Hylenex recombinant, is an rHuPH20 formulation specifically designed to facilitate subcutaneous fluid delivery for hydration. It also plays a crucial role in improving the dispersion and absorption of other injected drugs during subcutaneous urography, and aids in the resorption of radiopaque agents. Halozyme also offers several key therapeutics leveraging its platform, including Perjeta, RITUXAN HYCELA, and MabThera SC, which are used to treat non-Hodgkin lymphoma and chronic lymphocytic leukemia (CLL). RITUXAN SC is another offering for CLL patients, while HYQVIA addresses various immunodeficiency disorders. Their development pipeline boasts numerous investigational drugs, such as Tecentriq for non-small cell lung cancer, OCREVUS for multiple sclerosis, and DARZALEX, which targets amyloidosis, smoldering myeloma, and multiple myeloma. Other pipeline candidates include nivolumab for solid tumors, ARGX-113 (a human neonatal Fc receptor), ARGX-117 for autoimmune diseases, and BMS-986179, an anti-CD-73 antibody. Halozyme maintains extensive collaborations with prominent pharmaceutical companies like F. Hoffmann-La Roche, Pfizer Inc., Janssen Biotech, Inc., AbbVie, Inc., Eli Lilly and Company, Bristol-Myers Squibb Company, Alexion Pharma Holding, ARGENX BVBA, and Horizon Therapeutics plc. They also partner with research institutions such as the National Institute of Allergy and Infectious Diseases, the Centre for the AIDS Programme of Research in South Africa, and ViiV Healthcare Limited, particularly focusing on both small and large molecule targets for the treatment and prevention of HIV. The company was established in 1998.
News Sentiment (7d)
Based on only 1 article — low confidence
- Time to Buy Wide Moat & HALO ETFs? Zacks Investment Research
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD68.55
-0.02 (-0.03%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
2M
Beta
0.87
Float Shares
116.71M
Free Float %
98.5%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +6.81% | +7.60% | +4.59% | -7.79% | +0.42% | +5.39% | +6.53% | +115.07% | +66.97% | +727.65% | +1,568.94% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Analyst Consensus (27 ratings, all time)
Buy
Price Targets & DCF
Current price
68.55
Low
56.00
-18.3%
Consensus
75.00
+9.4%
Median
75.00
+9.4%
High
95.00
+38.6%
DCF (Unlevered)
148.22
+116.2%
DCF (Levered)
117.71
+71.7%
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
Ratings Trend (MoM)
67% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 2 | 0 |
| Buy | 4 | 0 |
| Hold | 2 | 0 |
| Sell | 1 | 0 |
| Strong Sell | 0 | 0 |
Price Target Summary
| Period | # Analysts | Avg Target |
|---|---|---|
| Last Month | 2 |
95.50
+39.3%
|
| Last Quarter | 4 |
90.00
+31.3%
|
| Last Year | 12 |
78.33
+14.3%
|
| All Time | 21 |
69.29
+1.1%
|
Quality scores
Altman Z-Score
3.96
Safe zone
Piotroski F-Score
7 / 9
Strong
MOAT Score
8 / 10
Strong MOAT
Composite Rating
B+
Overall Score
3 / 5
Medium
DCF Score
4 / 5
High
ROE Score
5 / 5
High
ROA Score
5 / 5
High
D/E Score
1 / 5
Low
P/E Score
2 / 5
Medium
P/Book Score
1 / 5
Low
Operational MOAT
✗ Below peers
-
Revenue growth Biotechnology: +1.6%+37.6% ★ Q1'26: +42.2% (vs Q1'25)
-
EPS growth Biotechnology: +29.7%-25.4% Q1'26: +31.2% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%+41.3% ★ Q1'26: +46.8% (vs Q1'25)
-
EBIT margin Biotechnology: +0.0%+58.5% ★ Q1'26: +0.0% (vs Q1'25)
-
ROIC Biotechnology: -16.1%— Q1'26: +0.0% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%-4.3% ★ Q1'26: -3.0% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×0.00× ★ Q1'26: 0.28× (vs Q1'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2012 actual |
Dec 2013 actual |
Dec 2015 actual |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 6 Rev. Ana. 4 EPS Ana. |
Dec 2027 5 Rev. Ana. 3 EPS Ana. |
Dec 2028 4 Rev. Ana. 2 EPS Ana. |
Dec 2029 3 Rev. Ana. 1 EPS Ana. |
Dec 2030 3 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
42.33M
est: 100.69M (-58.0%)
|
54.80M
est: 44.48M (+23.2%)
|
135.06M
est: 135.26M (-0.2%)
|
146.69M
est: 145.98M (+0.5%)
|
316.61M
est: 294.78M (+7.4%)
|
151.86M
est: 151.42M (+0.3%)
|
195.99M
est: 198.85M (-1.4%)
|
267.59M
est: 265.21M (+0.9%)
|
443.31M
est: 443.24M (+0.0%)
|
660.12M
est: 671.79M (-1.7%)
|
829.25M
est: 873.30M (-5.0%)
|
1.02B
est: 1.00B (+1.2%)
|
1.40B
est: 1.39B (+0.2%)
|
1.77B
1.73B – 1.79B
+26.8% YoY
|
2.01B
1.90B – 2.04B
+13.5% YoY
|
2.17B
2.17B – 2.17B
+8.0% YoY
|
2.01B
1.97B – 2.03B
-7.3% YoY
|
1.78B
1.75B – 1.80B
-11.3% YoY
|
| EBITDA |
-52.47M
est: -46.92M (-11.8%)
|
-78.98M
est: -59.50M (-32.7%)
|
-25.35M
est: -10.19M (-148.7%)
|
-79.47M
est: -95.78M (+17.0%)
|
83.16M
est: 71.96M (+15.6%)
|
-69.33M
est: -69.78M (+0.6%)
|
-56.56M
est: -35.21M (-60.6%)
|
152.96M
est: 154.54M (-1.0%)
|
259.04M
est: 187.53M (+38.1%)
|
315.51M
est: 243.51M (+29.6%)
|
451.95M
est: 658.55M (-31.4%)
|
656.54M
est: 756.41M (-13.2%)
|
904.34M
est: 1.05B (-13.9%)
|
1.33B
1.31B – 1.35B
+26.8% YoY
|
1.51B
1.44B – 1.54B
+13.5% YoY
|
1.63B
1.63B – 1.63B
+8.0% YoY
|
1.51B
1.48B – 1.53B
-7.3% YoY
|
1.34B
1.32B – 1.36B
-11.3% YoY
|
| EBIT |
-53.55M
est: -48.11M (-11.3%)
|
-80.21M
est: -60.61M (-32.3%)
|
-27.03M
est: -13.45M (-100.9%)
|
-81.88M
est: -100.28M (+18.3%)
|
81.00M
est: 66.22M (+22.3%)
|
-69.33M
est: -82.50M (+16.0%)
|
-60.62M
est: -44.86M (-35.2%)
|
149.68M
est: 145.34M (+3.0%)
|
256.04M
est: 210.60M (+21.6%)
|
265.87M
est: 239.79M (+10.9%)
|
367.09M
est: 569.22M (-35.5%)
|
575.23M
est: 653.81M (-12.0%)
|
816.29M
est: 908.39M (-10.1%)
|
1.15B
1.13B – 1.16B
+26.8% YoY
|
1.31B
1.24B – 1.33B
+13.5% YoY
|
1.41B
1.41B – 1.41B
+8.0% YoY
|
1.31B
1.28B – 1.32B
-7.3% YoY
|
1.16B
1.14B – 1.17B
-11.3% YoY
|
| Net Income |
-53.55M
est: -48.05M (-11.5%)
|
-83.48M
est: -62.93M (-32.6%)
|
-32.23M
est: -20.67M (-55.9%)
|
-103.02M
est: -124.09M (+17.0%)
|
62.97M
est: 43.33M (+45.3%)
|
-80.33M
est: -96.22M (+16.5%)
|
-72.24M
est: -48.19M (-49.9%)
|
129.09M
est: 129.76M (-0.5%)
|
402.71M
est: 279.99M (+43.8%)
|
202.13M
est: 233.71M (-13.5%)
|
281.59M
est: 322.62M (-12.7%)
|
444.09M
est: 512.14M (-13.3%)
|
316.89M
est: 804.58M (-60.6%)
|
998.04M
976.94M – 1.02B
+24.0% YoY
|
1.20B
1.11B – 1.30B
+20.5% YoY
|
1.36B
1.36B – 1.37B
+13.3% YoY
|
1.26B
1.22B – 1.27B
-8.0% YoY
|
1.10B
1.07B – 1.12B
-12.1% YoY
|
| SGA |
24.81M
est: 26.05M (-4.8%)
|
32.35M
est: 24.91M (+29.9%)
|
40.03M
est: 61.20M (-34.6%)
|
45.85M
est: 55.28M (-17.1%)
|
53.82M
est: 64.25M (-16.2%)
|
60.80M
est: 78.17M (-22.2%)
|
77.25M
est: 62.36M (+23.9%)
|
45.74M
est: 47.30M (-3.3%)
|
50.32M
est: 41.51M (+21.2%)
|
143.53M
est: 44.67M (+221.3%)
|
149.18M
est: 139.96M (+6.6%)
|
154.34M
est: 160.76M (-4.0%)
|
193.39M
est: 223.35M (-13.4%)
|
283.18M
277.57M – 286.14M
+26.8% YoY
|
321.44M
305.21M – 326.31M
+13.5% YoY
|
347.25M
347.15M – 347.35M
+8.0% YoY
|
321.77M
315.41M – 325.14M
-7.3% YoY
|
285.42M
279.78M – 288.42M
-11.3% YoY
|
| EPS |
-0.48
est: -0.59 (+17.9%)
|
-0.74
est: -0.46 (-62.6%)
|
-0.25
est: -0.37 (+31.6%)
|
-0.81
est: -0.87 (+6.5%)
|
0.46
est: 0.32 (+42.9%)
|
-0.56
est: -0.57 (+2.2%)
|
-0.50
est: -0.44 (-13.4%)
|
0.95
est: 0.93 (+2.6%)
|
2.86
est: 2.68 (+6.6%)
|
1.48
est: 1.32 (+12.4%)
|
2.13
est: 2.62 (-18.7%)
|
3.50
est: 4.13 (-15.2%)
|
2.64
est: 6.55 (-59.7%)
|
8.07
7.88 – 8.23
+23.1% YoY
|
9.93
8.93 – 10.49
+23.2% YoY
|
11.01
10.99 – 11.02
+10.8% YoY
|
10.13
9.87 – 10.27
-8.0% YoY
|
8.90
8.67 – 9.02
-12.1% YoY
|
Recent Grade Changes (3M)
| Date | Firm | Previous | New Grade | Action |
|---|---|---|---|---|
| 2026-04-29 | HC Wainwright & Co. | Buy | Buy | Maintain |
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-11 | B+ | 3/5 | 4/5 | 5/5 | 5/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-08 | B+ | 3/5 | 5/5 | 5/5 | 5/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-07 | B+ | 3/5 | 5/5 | 5/5 | 5/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-06 | B+ | 3/5 | 4/5 | 5/5 | 5/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-05 | B+ | 3/5 | 4/5 | 5/5 | 5/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-04 | B+ | 3/5 | 4/5 | 5/5 | 5/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-01 | B+ | 3/5 | 4/5 | 5/5 | 5/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-30 | B+ | 3/5 | 4/5 | 5/5 | 5/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-29 | B+ | 3/5 | 4/5 | 5/5 | 5/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-28 | B+ | 3/5 | 4/5 | 5/5 | 5/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-27 | B+ | 3/5 | 4/5 | 5/5 | 5/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-24 | B+ | 3/5 | 4/5 | 5/5 | 5/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-23 | B+ | 3/5 | 4/5 | 5/5 | 5/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-22 | B+ | 3/5 | 4/5 | 5/5 | 5/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-21 | B+ | 3/5 | 4/5 | 5/5 | 5/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-20 | B+ | 3/5 | 4/5 | 5/5 | 5/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-17 | B+ | 3/5 | 4/5 | 5/5 | 5/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-16 | B+ | 3/5 | 4/5 | 5/5 | 5/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-15 | B+ | 3/5 | 4/5 | 5/5 | 5/5 | 1/5 | 2/5 | 1/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
697.46M
OE per share TTM
5.75
Owner's Yield
8.89%
Maintenance CapEx ratio
2.75%
Maint CapEx / Avg PPE
7.0%
Ownership Overview
Ownership breakdown
At a glance
Institutional holders
323
Total invested
2.12B
Insider transactions (90d)
8
Beneficial owners (>5%)
22
Beneficial owners (>5%)
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | (1) BlackRock, Inc. | 18.21M | 13.60% | — | — | — | — | HC | Delaware | 2023-01-20 | ↗ |
| 2 | The Vanguard Group - 23-1945930 | 13.50M | 9.59% | — | 262.2K | 13.11M | 390.3K | IA | Pennsylvania For | 2022-02-10 | ↗ |
| 3 | Artisan Investments GP LLC | 9.51M | 6.80% | — | 7.89M | — | 9.51M | HC | Delaware | 2022-02-04 | ↗ |
| 4 | Artisan Partners Asset Management Inc. | 9.51M | 6.80% | — | 7.89M | — | 9.51M | HC | Delaware | 2022-02-04 | ↗ |
| 5 | Artisan Partners Holdings LP | 9.51M | 6.80% | — | 7.89M | — | 9.51M | HC | Delaware | 2022-02-04 | ↗ |
| 6 | Artisan Partners Limited Partnership | 9.51M | 6.80% | — | 7.89M | — | 9.51M | IA | Delaware | 2022-02-04 | ↗ |
| 7 | 10. | 7.96M | 5.40% | — | 7.96M | — | 7.96M | HC, CO | Switzerland | 2020-02-14 | ↗ |
| 8 | 2. | 7.96M | 5.40% | — | 7.96M | — | 7.96M | CO | Switzerland | 2020-02-14 | ↗ |
| 9 | Abigail P. Johnson | 6.77M | 5.23% | — | — | 6.77M | — | IN | Delaware | 2017-02-14 | ↗ |
| 10 | FMR LLC | 6.77M | 5.23% | 6.6K | — | 6.77M | — | HC | Delaware | 2017-02-14 | ↗ |
| 11 | STATE STREET CORPORATION | 6.64M | 5.20% | — | 6.13M | — | — | HC | MA | 2024-10-17 | ↗ |
| 12 | Tax ID # 57-1156902 | 4.53M | 3.18% | — | — | — | — | IA | State of Delaware | 2018-02-05 | ↗ |
| 13 | BB Biotech AG | 3.97M | 2.90% | — | 3.97M | — | 3.97M | HC, CO | Switzerland | 2021-02-12 | ↗ |
| 14 | Biotech Target N.V. | 3.97M | 2.90% | — | 3.97M | — | 3.97M | CO | Switzerland | 2021-02-12 | ↗ |
| 15 | 13-4093645 | 2.78M | 2.20% | 2.78M | — | 2.78M | — | IA, PN | Delaware | 2015-02-17 | ↗ |
| 16 | 46-3147749 | 2.78M | 2.20% | 2.78M | — | 2.78M | — | HC, OO | Delaware | 2015-02-17 | ↗ |
| 17 | Felix J. Baker | 2.78M | 2.20% | 2.78M | — | 2.78M | — | HC, IN | United States | 2015-02-17 | ↗ |
| 18 | Julian C. Baker | 2.78M | 2.20% | 2.78M | — | 2.78M | — | HC, IN | United States | 2015-02-17 | ↗ |
| 19 | Wynnefield Partners Small Cap Value, L.P. | 116.4K | 1.70% | 144.6K | — | 6.15M | 133.2K | PN | Pennsylvania | 2015-02-11 | ↗ |
| 20 | David L. Cohen | 10.00 | 12.00% | — | — | — | — | IN | Delaware | 2020-01-28 | ↗ |
| 21 | Harold J. Levy | 10.00 | 12.00% | — | — | — | — | IN | Delaware | 2020-01-28 | ↗ |
| 22 | Iridian Asset Management LLC | 10.00 | 12.00% | — | — | — | — | IA | Delaware | 2020-01-28 | ↗ |
Institutional Activity (13F)
Institutional ownership trend
From
To
13F snapshot — 2026 Q1
Investors holding
323
-302 vs prev Q
New positions
56
Closed positions
346
Increased
168
Reduced
99
Put/Call ratio
0.00
Calls held
—
Puts held
—
Top institutional holders
| # | Investor | Shares / Δ | Mkt value / Δ | Own% / Δ | Weight% / Δ | Avg px / Perf. | Hold / Status |
|---|---|---|---|---|---|---|---|
| 1 | MACQUARIE MANAGEMENT HOLDINGS, INC. | 1.52M +1.5M (+100.0%) | 102.19B +102.2B (+100.0%) | 1.29% +1.290 pp | 0.15% +0.154 pp | USD67.30 +0.0% | 1 qtrs NEW |
| 2 | — | 375.9K +375.9K (+100.0%) | 25.30B +25.3B (+100.0%) | 0.32% +0.321 pp | 0.64% +0.645 pp | USD67.30 +0.0% | 1 qtrs NEW |
| 3 | BLACKROCK, INC. | 13.15M +293.7K (+2.3%) | 885.25M -57.9M (-6.1%) | 11.18% +0.580 pp | 0.02% -0.002 pp | USD57.39 +17.3% | 6 qtrs — |
| 4 | VANGUARD GROUP INC | 11.57M -62.9K (-0.5%) | 778.45M -74.5M (-8.7%) | 9.83% +0.246 pp | 0.01% -0.002 pp | USD29.87 +125.3% | 77 qtrs — |
| 5 | STATE STREET CORP | 5.12M +102.5K (+2.0%) | 344.69M -23.4M (-6.4%) | 4.35% +0.216 pp | 0.01% -0.001 pp | USD32.22 +108.9% | 51 qtrs — |
| 6 | INVESCO LTD. | 3.65M +402.3K (+12.4%) | 245.51M +7.5M (+3.1%) | 3.10% +0.425 pp | 0.04% +0.000 pp | USD47.13 +42.8% | 43 qtrs — |
| 7 | ARROWSTREET CAPITAL, LIMITED PARTNERSHIP | 3.22M -68.2K (-2.1%) | 216.87M -24.5M (-10.1%) | 2.75% +0.037 pp | 0.13% -0.025 pp | USD57.04 +18.0% | 10 qtrs — |
| 8 | BANK OF AMERICA CORP /DE/ | 2.73M +757.6K (+38.3%) | 183.99M +39.1M (+26.9%) | 2.32% +0.695 pp | 0.01% +0.004 pp | USD50.45 +33.4% | 52 qtrs — |
| 9 | MORGAN STANLEY | 2.66M +920.7K (+53.0%) | 178.90M +51.5M (+40.4%) | 2.26% +0.827 pp | 0.01% +0.003 pp | USD53.82 +25.0% | 51 qtrs — |
| 10 | GEODE CAPITAL MANAGEMENT, LLC | 2.43M +1.9K (+0.1%) | 163.78M -14.6M (-8.2%) | 2.07% +0.064 pp | 0.01% -0.001 pp | USD25.34 +165.6% | 78 qtrs — |
| 11 | SNYDER CAPITAL MANAGEMENT L P | 2.40M -334.7K (-12.2%) | 161.47M -39.0M (-19.5%) | 2.05% -0.206 pp | 3.01% -0.782 pp | USD25.94 +159.4% | 40 qtrs — |
| 12 | DIMENSIONAL FUND ADVISORS LP | 2.10M +25.7K (+1.2%) | 141.61M -10.8M (-7.1%) | 1.80% +0.082 pp | 0.03% -0.003 pp | USD44.13 +52.5% | 32 qtrs — |
| 13 | NORGES BANK | 1.90M +1.9M (+100.0%) | 128.20M +128.2M (+100.0%) | 1.63% +1.625 pp | 0.01% +0.014 pp | USD67.30 +0.0% | 1 qtrs NEW |
| 14 | WILLIAM BLAIR INVESTMENT MANAGEMENT, LLC | 1.84M +1.8M (+100.0%) | 124.03M +124.0M (+100.0%) | 1.57% +1.572 pp | 0.35% +0.346 pp | USD67.30 +0.0% | 1 qtrs NEW |
| 15 | ALLIANCEBERNSTEIN L.P. | 1.84M -71.9K (-3.8%) | 123.53M -16.4M (-11.7%) | 1.56% -0.012 pp | 0.04% -0.005 pp | USD38.81 +73.4% | 61 qtrs — |
| 16 | D. E. SHAW & CO., INC. | 1.65M -1.0M (-37.8%) | 111.01M -83.4M (-42.9%) | 1.41% -0.777 pp | 0.06% -0.049 pp | USD63.91 +5.3% | 38 qtrs — |
| 17 | FEDERATED HERMES, INC. | 1.57M +123.9K (+8.5%) | 105.97M -422.6K (-0.4%) | 1.34% +0.148 pp | 0.18% -0.011 pp | USD65.53 +2.7% | 43 qtrs — |
| 18 | JUPITER ASSET MANAGEMENT LTD | 1.57M +769.0K (+96.1%) | 105.63M +46.9M (+79.9%) | 1.34% +0.679 pp | 0.85% +0.342 pp | USD61.72 +9.0% | 4 qtrs — |
| 19 | MILLENNIUM MANAGEMENT LLC | 1.46M +236.4K (+19.3%) | 98.52M +8.5M (+9.4%) | 1.24% +0.232 pp | 0.04% +0.003 pp | USD62.18 +8.2% | 26 qtrs — |
| 20 | WELLS FARGO & COMPANY/MN | 1.41M +819.9K (+140.0%) | 94.59M +51.6M (+120.2%) | 1.19% +0.712 pp | 0.02% +0.009 pp | USD55.68 +20.9% | 57 qtrs — |
| 21 | FULLER & THALER ASSET MANAGEMENT, INC. | 1.38M +8.4K (+0.6%) | 92.85M -7.7M (-7.7%) | 1.18% +0.047 pp | 0.31% -0.028 pp | USD50.48 +33.3% | 11 qtrs — |
| 22 | ROYAL LONDON ASSET MANAGEMENT LTD | 1.37M +228.0K (+19.9%) | 92.29M +8.4M (+10.1%) | 1.17% +0.228 pp | 0.19% +0.014 pp | USD59.47 +13.2% | 4 qtrs — |
| 23 | UBS GROUP AG | 1.37M -1.6M (-53.6%) | 91.91M -124.1M (-57.5%) | 1.16% -1.267 pp | 0.01% -0.019 pp | USD61.40 +9.6% | 45 qtrs — |
| 24 | CONGRESS ASSET MANAGEMENT CO /MA | 1.30M -134.4K (-9.4%) | 87.64M -17.7M (-16.8%) | 1.11% -0.077 pp | 0.62% -0.084 pp | USD54.58 +23.3% | 11 qtrs — |
| 25 | LSV ASSET MANAGEMENT | 1.30M +35.0K (+2.8%) | 87.56M -5.3M (-5.7%) | 1.11% +0.062 pp | 0.19% -0.014 pp | USD49.72 +35.4% | 9 qtrs — |
| 26 | MIZUHO MARKETS AMERICAS LLC | 1.27M +926.5K (+270.8%) | 85.38M +60.3M (+240.3%) | 1.08% +0.800 pp | 1.65% +1.177 pp | USD60.26 +11.7% | 14 qtrs — |
| 27 | GW&K INVESTMENT MANAGEMENT, LLC | 1.25M -7.1K (-0.6%) | 84.44M -8.1M (-8.7%) | 1.07% +0.031 pp | 0.73% -0.089 pp | USD40.82 +64.9% | 21 qtrs — |
| 28 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 1.24M -19.5K (-1.5%) | 83.58M -8.9M (-9.7%) | 1.06% +0.020 pp | 0.01% -0.002 pp | USD30.12 +123.4% | 75 qtrs — |
| 29 | CAISSE DE DEPOT ET PLACEMENT DU QUEBEC | 1.22M +447.4K (+57.6%) | 82.38M +25.4M (+44.6%) | 1.04% +0.400 pp | 0.14% +0.037 pp | USD60.39 +11.4% | 6 qtrs — |
| 30 | STEPHENS INVESTMENT MANAGEMENT GROUP LLC | 1.22M -1.5K (-0.1%) | 82.35M -7.5M (-8.3%) | 1.04% +0.034 pp | 1.07% -0.092 pp | USD38.83 +73.3% | 23 qtrs — |
| 31 | FRANKLIN RESOURCES INC | 1.21M +133.3K (+12.4%) | 81.41M +2.5M (+3.1%) | 1.03% +0.145 pp | 0.02% +0.000 pp | USD57.03 +18.0% | 21 qtrs — |
| 32 | AQR CAPITAL MANAGEMENT LLC | 1.16M +189.8K (+19.6%) | 77.96M +6.9M (+9.8%) | 0.99% +0.190 pp | 0.04% -0.005 pp | USD64.71 +4.0% | 66 qtrs — |
| 33 | NORTHERN TRUST CORP | 1.10M -70.8K (-6.1%) | 73.78M -11.8M (-13.8%) | 0.94% -0.027 pp | 0.01% -0.002 pp | USD24.16 +178.6% | 51 qtrs — |
| 34 | LOS ANGELES CAPITAL MANAGEMENT LLC | 1.10M +14.8K (+1.4%) | 70.83M -8.5M (-10.7%) | 0.93% +0.044 pp | 0.24% -0.028 pp | USD52.96 +27.1% | 34 qtrs — |
| 35 | FIRST TRUST ADVISORS LP | 1.01M +235.4K (+30.3%) | 68.09M +11.2M (+19.6%) | 0.86% +0.223 pp | 0.05% +0.007 pp | USD47.45 +41.8% | 37 qtrs — |
| 36 | BANK OF NEW YORK MELLON CORP | 961.1K -91.9K (-8.7%) | 64.68M -12.5M (-16.2%) | 0.82% -0.048 pp | 0.01% -0.004 pp | USD35.98 +87.0% | 66 qtrs — |
| 37 | PACER ADVISORS, INC. | 937.3K +458.4K (+95.7%) | 63.08M +28.0M (+79.6%) | 0.80% +0.405 pp | 0.16% +0.073 pp | USD69.72 -3.5% | 14 qtrs — |
| 38 | TD ASSET MANAGEMENT INC | 931.7K -103.5K (-10.0%) | 62.70M -13.2M (-17.4%) | 0.79% -0.058 pp | 0.05% -0.011 pp | USD40.76 +65.1% | 13 qtrs — |
| 39 | SEI INVESTMENTS CO | 901.1K +440.2K (+95.5%) | 60.65M +26.8M (+79.4%) | 0.77% +0.389 pp | 0.06% +0.024 pp | USD57.34 +17.4% | 44 qtrs — |
| 40 | CAPITAL WORLD INVESTORS | 879.9K +48.2K (+5.8%) | 59.22M -1.8M (-2.9%) | 0.75% +0.065 pp | 0.01% 0.000 pp | USD50.48 +33.3% | 5 qtrs — |
| 41 | JACOBS LEVY EQUITY MANAGEMENT, INC | 877.0K -21.2K (-2.4%) | 59.02M -6.9M (-10.4%) | 0.75% +0.008 pp | 0.23% -0.034 pp | USD54.16 +24.3% | 4 qtrs — |
| 42 | JANUS HENDERSON GROUP PLC | 864.0K -94.1K (-9.8%) | 58.14M -12.1M (-17.2%) | 0.74% -0.053 pp | 0.03% -0.006 pp | USD41.15 +63.5% | 22 qtrs — |
| 43 | BANK OF MONTREAL /CAN/ | 784.3K +368.7K (+88.7%) | 52.78M +22.3M (+73.2%) | 0.67% +0.327 pp | 0.02% +0.007 pp | USD54.43 +23.6% | 51 qtrs — |
| 44 | BOSTON TRUST WALDEN CORP | 781.8K -52.1K (-6.2%) | 52.62M -8.5M (-14.0%) | 0.67% -0.020 pp | 0.40% -0.052 pp | USD52.53 +28.1% | 7 qtrs — |
| 45 | VOLORIDGE INVESTMENT MANAGEMENT, LLC | 754.5K -303.4K (-28.7%) | 50.78M -26.8M (-34.6%) | 0.64% -0.231 pp | 0.18% -0.082 pp | USD73.34 -8.2% | 2 qtrs — |
| 46 | UBS ASSET MANAGEMENT AMERICAS INC | 733.6K +406.6K (+124.4%) | 49.37M +25.4M (+105.9%) | 0.63% +0.356 pp | 0.01% +0.005 pp | USD58.40 +15.2% | 57 qtrs — |
| 47 | TWO SIGMA INVESTMENTS, LP | 717.4K -598.6K (-45.5%) | 48.28M -48.2M (-50.0%) | 0.61% -0.475 pp | 0.07% -0.076 pp | USD67.95 -1.0% | 8 qtrs — |
| 48 | NUVEEN, LLC | 699.9K +46.8K (+7.2%) | 47.10M -797.2K (-1.7%) | 0.59% +0.057 pp | 0.01% 0.000 pp | USD66.40 +1.4% | 4 qtrs — |
| 49 | BNP PARIBAS ARBITRAGE, SNC | 633.5K -143.5K (-18.5%) | 42.64M -14.3M (-25.2%) | 0.54% -0.102 pp | 0.02% -0.011 pp | USD68.88 -2.3% | 51 qtrs — |
| 50 | ARROWMARK COLORADO HOLDINGS LLC | 626.2K -298.7K (-32.3%) | 42.14M -25.7M (-37.9%) | 0.53% -0.230 pp | 0.93% -0.332 pp | USD42.05 +60.0% | 12 qtrs — |
| 51 | ROYAL BANK OF CANADA | 617.4K -333.4K (-35.1%) | 41.55M -28.2M (-40.4%) | 0.52% -0.259 pp | 0.01% -0.005 pp | USD55.64 +21.0% | 51 qtrs — |
| 52 | VICTORY CAPITAL MANAGEMENT INC | 599.2K -23.9K (-3.8%) | 40.32M -5.4M (-11.8%) | 0.51% -0.002 pp | 0.02% -0.004 pp | USD47.68 +41.1% | 32 qtrs — |
| 53 | HANDELSBANKEN FONDER AB | 591.9K +203.5K (+52.4%) | 39.83M +11.4M (+39.8%) | 0.50% +0.185 pp | 0.12% +0.030 pp | USD62.62 +7.5% | 23 qtrs — |
| 54 | RENAISSANCE TECHNOLOGIES LLC | 562.7K -437.5K (-43.7%) | 37.87M -35.5M (-48.4%) | 0.48% -0.346 pp | 0.06% -0.038 pp | USD66.92 +0.6% | 33 qtrs — |
| 55 | BRIDGEWATER ASSOCIATES, LP | 561.6K +74.5K (+15.3%) | 37.79M +2.1M (+5.8%) | 0.48% +0.078 pp | 0.14% -0.002 pp | USD72.54 -7.2% | 2 qtrs — |
| 56 | EPOCH INVESTMENT PARTNERS, INC. | 533.4K -63.2K (-10.6%) | 35.90M -7.9M (-18.0%) | 0.46% -0.037 pp | 0.20% -0.036 pp | USD41.92 +60.5% | 13 qtrs — |
| 57 | AMERIPRISE FINANCIAL INC | 528.3K +216.1K (+69.2%) | 35.56M +12.7M (+55.3%) | 0.45% +0.193 pp | 0.01% +0.003 pp | USD59.95 +12.3% | 37 qtrs — |
| 58 | EMPOWERED FUNDS, LLC | 510.9K +39.8K (+8.5%) | 34.39M -165.4K (-0.5%) | 0.44% +0.048 pp | 0.27% -0.076 pp | USD53.67 +25.4% | 4 qtrs — |
| 59 | CITIGROUP INC | 504.1K -45.8K (-8.3%) | 33.93M -6.4M (-15.9%) | 0.43% -0.023 pp | 0.02% -0.003 pp | USD60.68 +10.9% | 54 qtrs — |
| 60 | MARSHALL WACE, LLP | 497.2K +103.4K (+26.3%) | 33.46M +4.6M (+15.9%) | 0.42% +0.098 pp | 0.03% +0.001 pp | USD64.51 +4.3% | 5 qtrs — |
| 61 | BOSTON PARTNERS | 487.1K +42.3K (+9.5%) | 33.11M +1.0M (+3.2%) | 0.42% +0.049 pp | 0.03% +0.001 pp | USD43.25 +55.6% | 10 qtrs — |
| 62 | RENAISSANCE GROUP LLC | 481.2K +2.4K (+0.5%) | 32.38M -2.7M (-7.8%) | 0.41% +0.016 pp | 1.30% -0.024 pp | USD73.31 -8.2% | 2 qtrs — |
| 63 | FISHER ASSET MANAGEMENT, LLC | 467.9K +57.0K (+13.9%) | 31.49M +1.4M (+4.5%) | 0.40% +0.061 pp | 0.01% 0.000 pp | USD36.67 +83.5% | 47 qtrs — |
| 64 | NATIXIS | 467.5K +341.9K (+272.3%) | 31.46M +22.3M (+241.6%) | 0.40% +0.295 pp | 0.11% +0.069 pp | USD68.92 -2.4% | 9 qtrs — |
| 65 | GOLDMAN SACHS GROUP INC | 458.1K -226.4K (-33.1%) | 30.83M -19.4M (-38.6%) | 0.39% -0.173 pp | 0.00% -0.002 pp | USD46.95 +43.3% | 73 qtrs — |
| 66 | GOTHAM ASSET MANAGEMENT, LLC | 439.7K +186.8K (+73.8%) | 29.59M +11.0M (+59.5%) | 0.37% +0.165 pp | 0.11% +0.027 pp | USD66.90 +0.6% | 27 qtrs — |
| 67 | JPMORGAN CHASE & CO | 434.5K -333.3K (-43.4%) | 29.24M -27.1M (-48.1%) | 0.37% -0.262 pp | 0.00% -0.002 pp | USD20.26 +232.2% | 51 qtrs — |
| 68 | KENNEDY CAPITAL MANAGEMENT LLC | 433.8K +50.2K (+13.1%) | 29.19M +1.1M (+3.8%) | 0.37% +0.054 pp | 0.62% -0.004 pp | USD40.50 +66.2% | 43 qtrs — |
| 69 | SQUAREPOINT OPS LLC | 413.5K +55.6K (+15.5%) | 27.83M +1.6M (+6.0%) | 0.35% +0.058 pp | 0.03% +0.003 pp | USD59.90 +12.4% | 3 qtrs — |
| 70 | QUBE RESEARCH & TECHNOLOGIES LTD | 412.4K -188.9K (-31.4%) | 27.76M -16.3M (-37.1%) | 0.35% -0.144 pp | 0.03% -0.017 pp | USD52.02 +29.4% | 15 qtrs — |
| 71 | METLIFE INVESTMENT MANAGEMENT, LLC | 401.7K +60.1K (+17.6%) | 27.04M +2.0M (+7.9%) | 0.34% +0.061 pp | 0.13% +0.011 pp | USD54.09 +24.4% | 33 qtrs — |
| 72 | AMERICAN CENTURY COMPANIES INC | 380.4K +208.9K (+121.7%) | 25.60M +13.0M (+103.5%) | 0.32% +0.183 pp | 0.01% +0.007 pp | USD56.15 +19.9% | 49 qtrs — |
| 73 | RETIREMENT SYSTEMS OF ALABAMA | 370.9K -284.0 (-0.1%) | 24.96M -2.3M (-8.3%) | 0.32% +0.011 pp | 0.08% -0.010 pp | USD49.03 +37.3% | 21 qtrs — |
| 74 | CANADA PENSION PLAN INVESTMENT BOARD | 363.1K +129.9K (+55.7%) | 24.44M +7.3M (+42.9%) | 0.31% +0.116 pp | 0.02% +0.004 pp | USD59.18 +13.7% | 12 qtrs — |
| 75 | CERITY PARTNERS LLC | 360.2K +11.9K (+3.4%) | 24.24M -1.3M (-5.1%) | 0.31% +0.020 pp | 0.04% -0.006 pp | USD54.97 +22.4% | 15 qtrs — |
| 76 | RHUMBLINE ADVISERS | 345.8K -18.4K (-5.0%) | 23.27M -3.4M (-12.9%) | 0.29% -0.006 pp | 0.02% -0.003 pp | USD32.53 +106.9% | 51 qtrs — |
| 77 | LEGAL & GENERAL GROUP PLC | 318.4K -16.1K (-4.8%) | 21.43M -3.1M (-12.6%) | 0.27% -0.004 pp | 0.00% -0.001 pp | USD43.59 +54.4% | 46 qtrs — |
| 78 | RUSSELL INVESTMENTS GROUP, LTD. | 307.8K +2.2K (+0.7%) | 20.72M -1.7M (-7.6%) | 0.26% +0.011 pp | 0.02% -0.003 pp | USD54.48 +23.5% | 37 qtrs — |
| 79 | SEGALL BRYANT & HAMILL, LLC | 307.2K +90.7K (+41.9%) | 20.68M +4.8M (+30.2%) | 0.26% +0.084 pp | 0.28% +0.068 pp | USD49.89 +34.9% | 14 qtrs — |
| 80 | RAYMOND JAMES FINANCIAL INC | 282.9K +1.5K (+0.5%) | 19.05M -1.6M (-7.7%) | 0.24% +0.009 pp | 0.01% -0.001 pp | USD50.53 +33.2% | 5 qtrs — |
| 81 | PRINCIPAL FINANCIAL GROUP INC | 252.1K -7.0K (-2.7%) | 16.96M -2.0M (-10.7%) | 0.22% +0.002 pp | 0.01% -0.001 pp | USD44.39 +51.6% | 65 qtrs — |
| 82 | BI ASSET MANAGEMENT FONDSMAEGLERSELSKAB A/S | 246.1K -42.8K (-14.8%) | 16.57M -4.6M (-21.8%) | 0.21% -0.028 pp | 0.15% -0.045 pp | USD53.27 +26.3% | 9 qtrs — |
| 83 | HANCOCK WHITNEY CORP | 242.5K -3.8K (-1.5%) | 16.32M -1.7M (-9.6%) | 0.21% +0.003 pp | 0.29% -0.034 pp | USD54.37 +23.8% | 31 qtrs — |
| 84 | PRICE T ROWE ASSOCIATES INC /MD/ | 242.0K -583.4K (-70.7%) | 16.29M -44.2M (-73.1%) | 0.21% -0.475 pp | 0.00% -0.005 pp | USD41.90 +60.6% | 75 qtrs — |
| 85 | CALIFORNIA PUBLIC EMPLOYEES RETIREMENT SYSTEM | 237.4K -12.1K (-4.9%) | 15.98M -2.3M (-12.7%) | 0.20% -0.003 pp | 0.01% -0.002 pp | USD34.03 +97.8% | 58 qtrs — |
| 86 | BARCLAYS PLC | 236.8K -69.2K (-22.6%) | 15.93M -1.6M (-9.0%) | 0.20% -0.051 pp | 0.00% -0.001 pp | USD48.86 +37.7% | 51 qtrs — |
| 87 | SOUTH STREET ADVISORS LLC | 231.8K -16.1K (-6.5%) | 15.60M -2.6M (-14.2%) | 0.20% -0.007 pp | 2.19% -0.192 pp | USD55.83 +20.5% | 6 qtrs — |
| 88 | SWISS NATIONAL BANK | 230.7K -8.2K (-3.4%) | 15.53M -2.0M (-11.4%) | 0.20% 0.000 pp | 0.01% -0.001 pp | USD19.51 +245.0% | 51 qtrs — |
| 89 | CRESSET ASSET MANAGEMENT, LLC | 222.7K -935.0 (-0.4%) | 14.99M -1.4M (-8.6%) | 0.19% +0.006 pp | 0.06% -0.006 pp | USD41.00 +64.1% | 11 qtrs — |
| 90 | CAPITAL FUND MANAGEMENT S.A. | 219.6K +6.8K (+3.2%) | 14.78M -824.8K (-5.3%) | 0.19% +0.012 pp | 0.04% +0.000 pp | USD62.67 +7.4% | 5 qtrs — |
| 91 | ENVESTNET ASSET MANAGEMENT INC | 219.2K -27.3K (-11.1%) | 14.75M -3.3M (-18.4%) | 0.19% -0.017 pp | 0.00% -0.001 pp | USD45.13 +49.1% | 29 qtrs — |
| 92 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | 213.3K -184.5K (-46.4%) | 14.36M -14.8M (-50.8%) | 0.18% -0.147 pp | 0.00% -0.002 pp | USD60.66 +10.9% | 51 qtrs — |
| 93 | LPL FINANCIAL LLC | 210.3K +15.4K (+7.9%) | 14.15M -142.6K (-1.0%) | 0.18% +0.019 pp | 0.00% 0.000 pp | USD51.93 +29.6% | 23 qtrs — |
| 94 | UNIVERSAL- BETEILIGUNGS- UND SERVICEGESELLSCHAFT MBH | 202.1K +6.7K (+3.4%) | 13.62M -718.8K (-5.0%) | 0.17% +0.011 pp | 0.02% -0.002 pp | USD50.61 +33.0% | 5 qtrs — |
| 95 | ADVISOR GROUP HOLDINGS, INC. | 199.3K -49.3K (-19.8%) | 13.41M -4.8M (-26.4%) | 0.17% -0.036 pp | 0.02% -0.006 pp | USD68.83 -2.2% | 24 qtrs — |
| 96 | INTECH INVESTMENT MANAGEMENT LLC | 197.2K +48.6K (+32.7%) | 13.27M +2.4M (+21.7%) | 0.17% +0.046 pp | 0.12% +0.021 pp | USD60.81 +10.7% | 7 qtrs — |
| 97 | CI PRIVATE WEALTH, LLC | 196.6K +184.7K (+1,554.7%) | 13.23M +12.4M (+1,418.5%) | 0.17% +0.158 pp | 0.02% +0.016 pp | USD66.69 +0.9% | 13 qtrs — |
| 98 | SUSQUEHANNA PORTFOLIO STRATEGIES, LLC | 188.1K -2.6K (-1.3%) | 12.66M -1.3M (-9.5%) | 0.16% +0.003 pp | 0.20% -0.026 pp | USD52.31 +28.7% | 3 qtrs — |
| 99 | JANE STREET GROUP, LLC | 164.3K -911.0K (-84.7%) | 11.06M -67.8M (-86.0%) | 0.14% -0.746 pp | 0.00% -0.010 pp | USD54.03 +24.6% | 35 qtrs — |
| 100 | SWEDBANK AB | 162.1K +14.9K (+10.1%) | 10.91M +113.9K (+1.1%) | 0.14% +0.017 pp | 0.01% 0.000 pp | USD43.55 +54.5% | 20 qtrs — |
Ownership breakdown by holder
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
1.50
Neutral
Ratio by volume
1.00
Neutral
Buys
15
Sells
10
Shares acquired
102.0K
Shares disposed
101.6K
Cash buys
—
Cash sales
7.00
Net activity
+391
Insider buys vs sells (history)
From
To
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2027-02-23 | Caudill Cortney | Officer | — | — | Performance Stock Unit | 9,246 | 0.00 | — | 0 | D | ↗ |
| 2026-05-05 | Posard Matthew L. | Director | A-Award | A | Common Stock | 3,796 | 0.00 | — | 77,835 | D | ↗ |
| 2026-05-05 | Lang James Paul | Director | A-Award | A | Option to Purchase Common Stock | 6,040 | 65.87 | 397.9K | 6,040 | D | ↗ |
| 2026-05-05 | Krishnan Mahesh | Director | A-Award | A | Common Stock | 3,796 | 0.00 | — | 14,462 | D | ↗ |
| 2026-05-05 | Henderson Jeffrey William | Director | A-Award | A | Common Stock | 3,796 | 0.00 | — | 36,572 | D | ↗ |
| 2026-05-05 | DUNCAN BARBARA GAYLE | Director | A-Award | A | Common Stock | 3,796 | 0.00 | — | 23,715 | D | ↗ |
| 2026-05-05 | Connaughton Bernadette | Director | A-Award | A | Common Stock | 6,796 | 0.00 | — | 45,294 | D | ↗ |
| 2026-05-01 | Connaughton Bernadette | Director | S-Sale | D | Common Stock | 1,625 | 63.48 | 103.2K | 38,498 | D | ↗ |
| 2026-04-06 | Torley Helen | Director / Officer | M-Exempt | A | Common Stock | 10,000 | 12.07 | 120.7K | 777,780 | D | ↗ |
| 2026-04-02 | Torley Helen | Director / Officer | M-Exempt | A | Common Stock | 20,000 | 12.07 | 241.4K | 787,780 | D | ↗ |
| 2026-04-01 | Torley Helen | Director / Officer | S-Sale | D | Common Stock | 19,000 | 65.36 | 1.24M | 768,780 | D | ↗ |
| 2026-04-01 | RAMSAY DAVID A | Officer | A-Award | A | Restricted Stock Units | 10,000 | 0.00 | — | 10,000 | D | ↗ |
| 2026-03-23 | RAMSAY DAVID A | Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2026-03-10 | Caudill Cortney | Officer | M-Exempt | A | Common Stock | 1,546 | 33.51 | 51.8K | 15,912 | D | ↗ |
| 2026-03-09 | Caudill Cortney | Officer | M-Exempt | D | Option to Purchase Common Stock | 20,000 | 33.51 | 670.2K | 69,224 | D | ↗ |
| 2026-03-04 | Torley Helen | Director / Officer | S-Sale | D | Common Stock | 7,329 | 69.94 | 512.6K | 770,451 | D | ↗ |
| 2026-03-03 | Torley Helen | Director / Officer | S-Sale | D | Common Stock | 13,481 | 68.85 | 928.2K | 774,299 | D | ↗ |
| 2026-03-02 | Torley Helen | Director / Officer | S-Sale | D | Common Stock | 15,322 | 69.80 | 1.07M | 768,358 | D | ↗ |
| 2026-02-23 | Torley Helen | Director / Officer | M-Exempt | D | Restricted Stock Units | 22,436 | 0.00 | — | 44,872 | D | ↗ |
| 2026-02-23 | Snyder Mark Howard | Officer | M-Exempt | D | Restricted Stock Units | 7,011 | 0.00 | — | 14,022 | D | ↗ |
| 2026-02-23 | LaBrosse Nicole | Officer | M-Exempt | D | Performance Stock Units | 6,688 | 0.00 | — | 36,357 | D | ↗ |
| 2026-02-20 | Torley Helen | Director / Officer | M-Exempt | A | Common Stock | 16,757 | 0.00 | — | 766,488 | D | ↗ |
| 2026-02-20 | Snyder Mark Howard | Officer | M-Exempt | D | Restricted Stock Units | 5,332 | 0.00 | — | 15,995 | D | ↗ |
| 2026-02-20 | LaBrosse Nicole | Officer | F-InKind | D | Common Stock | 2,876 | 70.98 | 204.1K | 35,414 | D | ↗ |
| 2026-02-20 | Caudill Cortney | Officer | — | — | Restricted Stock Unit | 10,664 | 0.00 | — | 0 | D | ↗ |
| 2026-02-16 | Torley Helen | Director / Officer | M-Exempt | A | Common Stock | 21,009 | 0.00 | — | 729,728 | D | ↗ |
| 2026-02-16 | Snyder Mark Howard | Officer | M-Exempt | D | Restricted Stock Units | 4,796 | 0.00 | — | 4,796 | D | ↗ |
| 2026-02-16 | LaBrosse Nicole | Officer | M-Exempt | D | Performance Stock Units | 13,351 | 0.00 | — | 0 | D | ↗ |
| 2026-02-09 | Torley Helen | Director / Officer | A-Award | A | Restricted Stock Units | 50,013 | 0.00 | — | 50,013 | D | ↗ |
| 2026-02-09 | Snyder Mark Howard | Officer | A-Award | A | Performance Stock Units | 29,502 | 0.00 | — | 29,502 | D | ↗ |
| 2026-02-09 | LaBrosse Nicole | Officer | A-Award | A | Performance Stock Units | 29,502 | 0.00 | — | 29,502 | D | ↗ |
| 2026-02-09 | Caudill Cortney | Officer | A-Award | A | Option to Purchase Common Stock | 14,047 | 80.48 | 1.13M | 14,047 | D | ↗ |
| 2026-02-05 | Torley Helen | Director / Officer | S-Sale | D | Common Stock | 5,376 | 78.38 | 421.4K | 713,343 | D | ↗ |
| 2026-02-04 | Torley Helen | Director / Officer | M-Exempt | A | Common Stock | 20,000 | 12.07 | 241.4K | 728,719 | D | ↗ |
| 2026-02-03 | Torley Helen | Director / Officer | S-Sale | D | Common Stock | 2,551 | 74.88 | 191.0K | 726,168 | D | ↗ |
| 2026-01-05 | Connaughton Bernadette | Director | S-Sale | D | Common Stock | 2,000 | 70.25 | 140.5K | 40,123 | D | ↗ |
| 2026-01-03 | Snyder Mark Howard | Officer | M-Exempt | A | Common Stock | 7,611 | 0.00 | — | 38,424 | D | ↗ |
| 2026-01-02 | Lang James Paul | Director | A-Award | A | Option to Purchase Common Stock | 1,342 | 70.31 | 94.4K | 1,342 | D | ↗ |
| 2025-12-09 | Torley Helen | Director / Officer | A-Award | A | Performance Stock Units | 165,522 | 0.00 | — | 165,522 | D | ↗ |
| 2025-12-04 | Lang James Paul | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2025-12-01 | Torley Helen | Director / Officer | S-Sale | D | Common Stock | 5,402 | 69.44 | 375.1K | 709,480 | D | ↗ |
| 2025-12-01 | Connaughton Bernadette | Director | S-Sale | D | Common Stock | 829 | 71.60 | 59.4K | 42,123 | D | ↗ |
| 2025-11-26 | Torley Helen | Director / Officer | G-Gift | D | Common Stock | 25,000 | 0.00 | — | 708,719 | D | ↗ |
| 2025-11-12 | Torley Helen | Director / Officer | M-Exempt | D | Option to Purchase Common Stock | 20,000 | 8.11 | 162.2K | 16,569 | D | ↗ |
| 2025-11-11 | Torley Helen | Director / Officer | M-Exempt | D | Option to Purchase Common Stock | 20,000 | 8.11 | 162.2K | 36,569 | D | ↗ |
| 2025-11-10 | Torley Helen | Director / Officer | S-Sale | D | Common Stock | 100 | 69.30 | 6.9K | 733,719 | D | ↗ |
| 2025-11-10 | Connaughton Bernadette | Director | S-Sale | D | Common Stock | 2,000 | 68.48 | 137.0K | 42,952 | D | ↗ |
| 2025-11-01 | Caudill Cortney | Officer | S-Sale | D | Common Stock | 4,263 | 65.19 | 277.9K | 12,737 | D | ↗ |
| 2025-10-03 | Torley Helen | Director / Officer | M-Exempt | A | Common Stock | 20,000 | 8.11 | 162.2K | 753,719 | D | ↗ |
| 2025-10-03 | Caudill Cortney | Officer | A-Award | A | Restricted Stock Units | 3,625 | 0.00 | — | 3,625 | D | ↗ |
| 2025-10-02 | Torley Helen | Director / Officer | S-Sale | D | Common Stock | 6,600 | 70.51 | 465.4K | 747,119 | D | ↗ |
| 2025-10-01 | Torley Helen | Director / Officer | S-Sale | D | Common Stock | 11,705 | 75.11 | 879.2K | 742,014 | D | ↗ |
| 2025-10-01 | Connaughton Bernadette | Director | S-Sale | D | Common Stock | 500 | 75.70 | 37.9K | 44,952 | D | ↗ |
| 2025-10-01 | Caudill Cortney | Officer | — | — | Common Stock | 0 | 0.00 | — | 7,674 | D | ↗ |
| 2025-09-22 | LaBrosse Nicole | Officer | S-Sale | D | Common Stock | 314 | 78.67 | 24.7K | 22,079 | D | ↗ |
| 2025-09-10 | LaBrosse Nicole | Officer | M-Exempt | A | Common Stock | 1,135 | 12.49 | 14.2K | 44,306 | D | ↗ |
| 2025-09-04 | Torley Helen | Director / Officer | M-Exempt | A | Common Stock | 20,000 | 8.11 | 162.2K | 753,719 | D | ↗ |
| 2025-09-03 | Torley Helen | Director / Officer | S-Sale | D | Common Stock | 9,500 | 74.22 | 705.1K | 744,219 | D | ↗ |
| 2025-09-02 | Torley Helen | Director / Officer | M-Exempt | D | Option to Purchase Common Stock | 20,000 | 8.11 | 162.2K | 176,569 | D | ↗ |
| 2025-09-02 | Connaughton Bernadette | Director | S-Sale | D | Common Stock | 100 | 71.71 | 7.2K | 50,852 | D | ↗ |
| 2025-08-13 | Torley Helen | Director / Officer | M-Exempt | A | Common Stock | 20,000 | 8.11 | 162.2K | 753,719 | D | ↗ |
| 2025-08-12 | Torley Helen | Director / Officer | S-Sale | D | Common Stock | 6,958 | 64.00 | 445.3K | 733,719 | D | ↗ |
| 2025-08-11 | Torley Helen | Director / Officer | S-Sale | D | Common Stock | 18,717 | 63.01 | 1.18M | 735,002 | D | ↗ |
| 2025-07-10 | Torley Helen | Director / Officer | M-Exempt | A | Common Stock | 20,000 | 8.11 | 162.2K | 753,719 | D | ↗ |
| 2025-07-09 | Torley Helen | Director / Officer | S-Sale | D | Common Stock | 208 | 57.08 | 11.9K | 733,719 | D | ↗ |
| 2025-07-08 | Torley Helen | Director / Officer | M-Exempt | D | Option to Purchase Common Stock | 20,000 | 8.11 | 162.2K | 296,569 | D | ↗ |
| 2025-06-24 | Torley Helen | Director / Officer | S-Sale | D | Common Stock | 15,511 | 53.91 | 836.2K | 733,719 | D | ↗ |
| 2025-06-23 | Torley Helen | Director / Officer | M-Exempt | D | Option to Purchase Common Stock | 20,000 | 8.11 | 162.2K | 336,569 | D | ↗ |
| 2025-06-20 | Torley Helen | Director / Officer | M-Exempt | D | Option to Purchase Common Stock | 20,000 | 8.11 | 162.2K | 356,569 | D | ↗ |
| 2025-06-12 | Snyder Mark Howard | Officer | M-Exempt | A | Common Stock | 5,035 | 0.00 | — | 33,524 | D | ↗ |
| 2025-05-01 | Posard Matthew L. | Director | A-Award | A | Option to Purchase Common Stock | 5,750 | 60.03 | 345.2K | 5,750 | D | ↗ |
| 2025-05-01 | Miyashita Akiko Moni | Director | A-Award | A | Option to Purchase Common Stock | 5,750 | 60.03 | 345.2K | 5,750 | D | ↗ |
| 2025-05-01 | Krishnan Mahesh | Director | A-Award | A | Common Stock | 4,165 | 0.00 | — | 10,666 | D | ↗ |
| 2025-05-01 | Henderson Jeffrey William | Director | A-Award | A | Common Stock | 4,165 | 0.00 | — | 32,776 | D | ↗ |
| 2025-05-01 | Duncan Barbara Gayle | Director | A-Award | A | Option to Purchase Common Stock | 5,750 | 60.03 | 345.2K | 5,750 | D | ↗ |
| 2025-05-01 | Connaughton Bernadette | Director | A-Award | A | Option to Purchase Common Stock | 5,750 | 60.03 | 345.2K | 5,750 | D | ↗ |
| 2025-04-28 | Henderson Jeffrey William | Director | S-Sale | D | Common Stock | 200 | 61.00 | 12.2K | 28,611 | D | ↗ |
| 2025-04-01 | Henderson Jeffrey William | Director | S-Sale | D | Common Stock | 503 | 64.05 | 32.2K | 33,108 | D | ↗ |
| 2025-03-03 | Henderson Jeffrey William | Director | S-Sale | D | Common Stock | 1,795 | 57.93 | 104.0K | 36,816 | D | ↗ |
| 2025-02-27 | LaBarre Michael J. | Officer | S-Sale | D | Common Stock | 1,597 | 58.25 | 93.0K | 173,856 | D | ↗ |
| 2025-02-26 | LaBarre Michael J. | Officer | S-Sale | D | Common Stock | 9,400 | 58.09 | 546.1K | 176,053 | D | ↗ |
| 2025-02-25 | LaBarre Michael J. | Officer | S-Sale | D | Common Stock | 9,300 | 58.01 | 539.5K | 186,153 | D | ↗ |
| 2025-02-23 | Torley Helen | Director / Officer | M-Exempt | D | Restricted Stock Units | 22,436 | 0.00 | — | 67,308 | D | ↗ |
| 2025-02-23 | Snyder Mark Howard | Officer | M-Exempt | D | Restricted Stock Units | 7,012 | 0.00 | — | 21,033 | D | ↗ |
| 2025-02-23 | LaBrosse Nicole | Officer | M-Exempt | D | Restricted Stock Units | 6,688 | 0.00 | — | 20,063 | D | ↗ |
| 2025-02-23 | LaBarre Michael J. | Officer | M-Exempt | D | Restricted Stock Units | 4,747 | 0.00 | — | 14,238 | D | ↗ |
| 2025-02-20 | Torley Helen | Director / Officer | A-Award | A | Restricted Stock Units | 67,027 | 0.00 | — | 67,027 | D | ↗ |
| 2025-02-20 | Snyder Mark Howard | Officer | A-Award | A | Option to Purchase Common Stock | 22,603 | 57.44 | 1.30M | 22,603 | D | ↗ |
| 2025-02-20 | LaBrosse Nicole | Officer | A-Award | A | Option to Purchase Common Stock | 22,603 | 57.44 | 1.30M | 22,603 | D | ↗ |
| 2025-02-20 | LaBarre Michael J. | Officer | A-Award | A | Restricted Stock Units | 11,230 | 0.00 | — | 11,230 | D | ↗ |
| 2025-02-16 | Torley Helen | Director / Officer | M-Exempt | A | Common Stock | 71,810 | 0.00 | — | 744,548 | D | ↗ |
| 2025-02-16 | Snyder Mark Howard | Officer | M-Exempt | D | Performance Stock Units | 17,409 | 0.00 | — | 0 | D | ↗ |
| 2025-02-16 | LaBrosse Nicole | Officer | M-Exempt | D | Restricted Stock Units | 5,329 | 0.00 | — | 10,658 | D | ↗ |
| 2025-02-16 | LaBarre Michael J. | Officer | M-Exempt | D | Restricted Stock Units | 6,112 | 0.00 | — | 6,112 | D | ↗ |
| 2025-02-15 | Torley Helen | Director / Officer | M-Exempt | D | Restricted Stock Units | 13,092 | 0.00 | — | 0 | D | ↗ |
| 2025-02-15 | LaBrosse Nicole | Officer | F-InKind | D | Common Stock | 741 | 58.29 | 43.2K | 15,993 | D | ↗ |
| 2025-02-15 | LaBarre Michael J. | Officer | M-Exempt | D | Restricted Stock Units | 3,386 | 0.00 | — | 0 | D | ↗ |
| 2025-02-12 | Torley Helen | Director / Officer | A-Award | A | Performance Stock Unit | 23,260 | 0.00 | — | 23,260 | D | ↗ |
| 2025-02-12 | Snyder Mark Howard | Officer | A-Award | A | Performance Stock Unit | 7,269 | 0.00 | — | 7,269 | D | ↗ |
| 2025-02-12 | LaBrosse Nicole | Officer | A-Award | A | Performance Stock Unit | 6,935 | 0.00 | — | 6,935 | D | ↗ |
| 2025-02-12 | LaBarre Michael J. | Officer | A-Award | A | Performance Stock Units | 20,342 | 0.00 | — | 20,342 | D | ↗ |
| 2025-02-03 | Henderson Jeffrey William | Director | S-Sale | D | Common Stock | 1,100 | 55.94 | 61.5K | 42,511 | D | ↗ |
| 2025-01-06 | Henderson Jeffrey William | Director | S-Sale | D | Common Stock | 10,000 | 50.01 | 500.1K | 43,611 | D | ↗ |
| 2025-01-03 | Snyder Mark Howard | Officer | M-Exempt | A | Common Stock | 7,611 | 0.00 | — | 19,291 | D | ↗ |
| 2024-11-29 | Torley Helen | Director / Officer | G-Gift | D | Common Stock | 10,000 | 0.00 | — | 666,744 | D | ↗ |
| 2024-11-29 | MATSUI CONNIE | Director | G-Gift | D | Common Stock | 10,470 | 0.00 | — | 183,035 | D | ↗ |
| 2024-11-01 | Caudill Cortney | Officer | — | — | Option to Purchase Common Stock | 89,224 | 33.51 | 2.99M | 0 | D | ↗ |
| 2024-10-16 | LaBarre Michael J. | Officer | M-Exempt | A | Common Stock | 10,000 | 19.98 | 199.8K | 183,756 | D | ↗ |
| 2024-10-15 | LaBarre Michael J. | Officer | M-Exempt | A | Common Stock | 5,509 | 16.65 | 91.7K | 179,265 | D | ↗ |
| 2024-10-09 | Torley Helen | Director / Officer | S-Sale | D | Common Stock | 1,615 | 53.31 | 86.1K | 679,148 | D | ↗ |
| 2024-10-08 | Torley Helen | Director / Officer | S-Sale | D | Common Stock | 9,100 | 53.94 | 490.8K | 677,644 | D | ↗ |
| 2024-09-26 | Torley Helen | Director / Officer | S-Sale | D | Common Stock | 10,000 | 56.10 | 561.0K | 676,744 | D | ↗ |
| 2024-09-25 | Torley Helen | Director / Officer | M-Exempt | D | Option to Purchase Common Stock | 10,000 | 13.87 | 138.7K | 30,000 | D | ↗ |
| 2024-09-24 | Torley Helen | Director / Officer | M-Exempt | D | Option to Purchase Common Stock | 10,000 | 13.87 | 138.7K | 40,000 | D | ↗ |
| 2024-09-18 | LaBarre Michael J. | Officer | M-Exempt | A | Common Stock | 10,000 | 16.65 | 166.5K | 183,756 | — | ↗ |
| 2024-09-17 | LaBarre Michael J. | Officer | S-Sale | D | Common Stock | 10,000 | 62.88 | 628.8K | 173,756 | — | ↗ |
| 2024-09-12 | Torley Helen | Director / Officer | S-Sale | D | Common Stock | 10,000 | 59.20 | 592.0K | 676,744 | — | ↗ |
| 2024-09-11 | Torley Helen | Director / Officer | S-Sale | D | Common Stock | 10,000 | 59.09 | 590.9K | 676,744 | — | ↗ |
| 2024-09-10 | Torley Helen | Director / Officer | S-Sale | D | Common Stock | 10,000 | 59.09 | 590.9K | 676,744 | — | ↗ |
| 2024-08-27 | LaBarre Michael J. | Officer | M-Exempt | A | Common Stock | 5,580 | 18.41 | 102.7K | 173,756 | — | ↗ |
| 2024-08-21 | LaBarre Michael J. | Officer | S-Sale | D | Common Stock | 9,900 | 61.74 | 611.2K | 168,276 | — | ↗ |
| 2024-08-20 | LaBarre Michael J. | Officer | S-Sale | D | Common Stock | 10,000 | 61.06 | 610.6K | 168,176 | — | ↗ |
| 2024-08-15 | Torley Helen | Director / Officer | M-Exempt | D | Option to Purchase Common Stock | 10,000 | 13.87 | 138.7K | 80,000 | — | ↗ |
| 2024-08-14 | Torley Helen | Director / Officer | S-Sale | D | Common Stock | 200 | 58.17 | 11.6K | 676,744 | — | ↗ |
| 2024-08-14 | Posard Matthew L. | Director | S-Sale | D | Common Stock | 9,881 | 57.70 | 570.1K | 69,874 | — | ↗ |
| 2024-08-13 | Torley Helen | Director / Officer | S-Sale | D | Common Stock | 10,000 | 56.25 | 562.5K | 676,744 | — | ↗ |
| 2024-08-13 | Posard Matthew L. | Director | S-Sale | D | Common Stock | 10,000 | 56.19 | 561.9K | 79,755 | — | ↗ |
| 2024-08-12 | Posard Matthew L. | Director | S-Sale | D | Common Stock | 10,000 | 55.72 | 557.2K | 89,755 | — | ↗ |
| 2024-07-24 | LaBarre Michael J. | Officer | M-Exempt | D | Option to Purchase Common Stock | 8,285 | 16.65 | 137.9K | 51,861 | — | ↗ |
| 2024-07-23 | LaBarre Michael J. | Officer | M-Exempt | D | Option to Purchase Common Stock | 10,000 | 8.11 | 81.1K | 1,715 | — | ↗ |
| 2024-07-22 | LaBrosse Nicole | Officer | M-Exempt | A | Common Stock | 4,008 | 22.50 | 90.2K | 19,488 | — | ↗ |
| 2024-06-28 | LaBrosse Nicole | Officer | S-Sale | D | Common Stock | 10,000 | 52.04 | 520.4K | 15,480 | — | ↗ |
| 2024-06-27 | LaBrosse Nicole | Officer | M-Exempt | D | Option to Purchase Common Stock | 10,000 | 22.50 | 225.0K | 15,000 | — | ↗ |
| 2024-06-26 | LaBrosse Nicole | Officer | M-Exempt | D | Option to Purchase Common Stock | 10,000 | 22.50 | 225.0K | 25,000 | — | ↗ |
| 2024-06-18 | LaBarre Michael J. | Officer | M-Exempt | A | Common Stock | 10,000 | 8.11 | 81.1K | 178,176 | — | ↗ |
| 2024-06-12 | Snyder Mark Howard | Officer | A-Award | A | Restricted Stock Units | 20,137 | 0.00 | — | 20,137 | — | ↗ |
| 2024-06-12 | Posard Matthew L. | Director | S-Sale | D | Common Stock | 10,000 | 50.62 | 506.2K | 99,755 | — | ↗ |
| 2024-06-11 | Posard Matthew L. | Director | S-Sale | D | Common Stock | 10,000 | 50.01 | 500.1K | 109,755 | — | ↗ |
| 2024-05-22 | LaBarre Michael J. | Officer | M-Exempt | D | Option to Purchase Common Stock | 10,000 | 8.11 | 81.1K | 21,715 | — | ↗ |
| 2024-05-21 | LaBarre Michael J. | Officer | S-Sale | D | Common Stock | 10,000 | 45.16 | 451.6K | 168,176 | — | ↗ |
| 2024-04-25 | Posard Matthew L. | Director | A-Award | A | Option to Purchase Common Stock | 8,804 | 38.46 | 338.6K | 8,804 | — | ↗ |
| 2024-04-25 | Miyashita Akiko Moni | Director | A-Award | A | Option to Purchase Common Stock | 8,804 | 38.46 | 338.6K | 8,804 | — | ↗ |
| 2024-04-25 | MATSUI CONNIE | Director | A-Award | A | Option to Purchase Common Stock | 8,804 | 38.46 | 338.6K | 8,804 | — | ↗ |
| 2024-04-25 | Krishnan Mahesh | Director | A-Award | A | Common Stock | 6,501 | 0.00 | — | 6,501 | — | ↗ |
| 2024-04-25 | Henderson Jeffrey William | Director | A-Award | A | Option to Purchase Common Stock | 8,804 | 38.46 | 338.6K | 8,804 | — | ↗ |
| 2024-04-25 | Duncan Barbara Gayle | Director | A-Award | A | Option to Purchase Common Stock | 8,804 | 38.46 | 338.6K | 8,804 | — | ↗ |
| 2024-04-25 | Connaughton Bernadette | Director | A-Award | A | Option to Purchase Common Stock | 8,804 | 38.46 | 338.6K | 8,804 | — | ↗ |
| 2024-04-17 | LaBarre Michael J. | Officer | M-Exempt | A | Common Stock | 10,000 | 8.11 | 81.1K | 178,176 | — | ↗ |
| 2024-04-16 | LaBarre Michael J. | Officer | M-Exempt | D | Option to Purchase Common Stock | 10,000 | 8.11 | 81.1K | 51,715 | — | ↗ |
| 2024-03-26 | LaBarre Michael J. | Officer | M-Exempt | A | Common Stock | 2,890 | 8.11 | 23.4K | 168,176 | — | ↗ |
| 2024-03-13 | LaBarre Michael J. | Officer | M-Exempt | A | Common Stock | 6,449 | 12.07 | 77.8K | 163,007 | — | ↗ |
| 2024-03-12 | LaBarre Michael J. | Officer | M-Exempt | A | Common Stock | 10,000 | 12.07 | 120.7K | 166,558 | — | ↗ |
| 2024-02-28 | LaBarre Michael J. | Officer | M-Exempt | A | Common Stock | 7,471 | 8.11 | 60.6K | 164,029 | — | ↗ |
| 2024-02-27 | LaBarre Michael J. | Officer | S-Sale | D | Common Stock | 10,000 | 39.95 | 399.5K | 159,087 | — | ↗ |
| 2024-02-23 | Torley Helen | Director / Officer | A-Award | A | Restricted Stock Units | 89,744 | 0.00 | — | 89,744 | — | ↗ |
| 2024-02-23 | Snyder Mark Howard | Officer | A-Award | A | Restricted Stock Units | 28,045 | 0.00 | — | 28,045 | — | ↗ |
| 2024-02-23 | LaBrosse Nicole | Officer | A-Award | A | Restricted Stock Units | 26,751 | 0.00 | — | 26,751 | — | ↗ |
| 2024-02-23 | LaBarre Michael J. | Officer | A-Award | A | Restricted Stock Units | 18,985 | 0.00 | — | 18,985 | — | ↗ |
| 2024-02-16 | Torley Helen | Director / Officer | M-Exempt | D | Restricted Stock Units | 21,009 | 0.00 | — | 42,018 | — | ↗ |
| 2024-02-16 | Snyder Mark Howard | Officer | F-InKind | D | Common Stock | 2,577 | 36.10 | 93.0K | 11,680 | — | ↗ |
| 2024-02-16 | LaBrosse Nicole | Officer | M-Exempt | D | Restricted Stock Units | 5,329 | 0.00 | — | 15,987 | — | ↗ |
| 2024-02-16 | LaBarre Michael J. | Officer | M-Exempt | D | Restricted Stock Units | 4,264 | 0.00 | — | 12,789 | — | ↗ |
| 2024-02-15 | Torley Helen | Director / Officer | M-Exempt | D | Restricted Stock Units | 13,092 | 0.00 | — | 13,092 | — | ↗ |
| 2024-02-15 | LaBrosse Nicole | Officer | M-Exempt | D | Restricted Stock Units | 1,254 | 0.00 | — | 1,254 | — | ↗ |
| 2024-02-15 | LaBarre Michael J. | Officer | M-Exempt | D | Restricted Stock Units | 3,386 | 0.00 | — | 3,386 | — | ↗ |
| 2024-02-10 | Torley Helen | Director / Officer | M-Exempt | D | Restricted Stock Units | 31,281 | 0.00 | — | 0 | — | ↗ |
| 2024-02-10 | LaBrosse Nicole | Officer | F-InKind | D | Common Stock | 1,477 | 35.49 | 52.4K | 10,091 | — | ↗ |
| 2024-02-10 | LaBarre Michael J. | Officer | F-InKind | D | Common Stock | 2,901 | 35.49 | 103.0K | 157,143 | — | ↗ |
| 2024-01-17 | LaBarre Michael J. | Officer | M-Exempt | A | Common Stock | 10,000 | 12.07 | 120.7K | 161,911 | — | ↗ |
| 2024-01-16 | LaBarre Michael J. | Officer | M-Exempt | D | Option to Purchase Common Stock | 10,000 | 12.07 | 120.7K | 34,885 | — | ↗ |
| 2024-01-03 | Snyder Mark Howard | Officer | M-Exempt | D | Restricted Stock Units | 7,611 | 0.00 | — | 15,222 | — | ↗ |
| 2023-12-13 | LaBarre Michael J. | Officer | S-Sale | D | Common Stock | 10,000 | 40.39 | 403.9K | 151,911 | — | ↗ |
| 2023-12-12 | LaBarre Michael J. | Officer | S-Sale | D | Common Stock | 9,357 | 39.58 | 370.3K | 152,554 | — | ↗ |
| 2023-11-15 | LaBarre Michael J. | Officer | S-Sale | D | Common Stock | 10,000 | 39.79 | 397.9K | 151,911 | — | ↗ |
| 2023-11-14 | LaBarre Michael J. | Officer | M-Exempt | D | Option to Purchase Common Stock | 1,708 | 16.78 | 28.7K | 292 | — | ↗ |
| 2023-10-17 | LaBarre Michael J. | Officer | S-Sale | D | Common Stock | 10,000 | 36.52 | 365.2K | 151,911 | — | ↗ |
| 2023-09-19 | LaBarre Michael J. | Officer | M-Exempt | A | Common Stock | 10,000 | 19.98 | 199.8K | 161,911 | — | ↗ |
| 2023-08-31 | Torley Helen | Director / Officer | M-Exempt | A | Common Stock | 10,000 | 13.87 | 138.7K | 633,666 | — | ↗ |
| 2023-08-30 | Torley Helen | Director / Officer | M-Exempt | D | Option to Purchase Common Stock | 10,000 | 13.87 | 138.7K | 120,000 | — | ↗ |
| 2023-08-29 | Torley Helen | Director / Officer | M-Exempt | D | Option to Purchase Common Stock | 10,000 | 13.87 | 138.7K | 130,000 | — | ↗ |
| 2023-08-22 | LaBarre Michael J. | Officer | M-Exempt | A | Common Stock | 8,075 | 19.98 | 161.3K | 159,986 | — | ↗ |
| 2023-08-17 | Torley Helen | Director / Officer | M-Exempt | A | Common Stock | 10,000 | 13.87 | 138.7K | 633,666 | — | ↗ |
| 2023-08-16 | Torley Helen | Director / Officer | S-Sale | D | Common Stock | 10,000 | 43.53 | 435.3K | 623,666 | — | ↗ |
| 2023-08-15 | Torley Helen | Director / Officer | M-Exempt | D | Option to Purchase Common Stock | 10,000 | 13.87 | 138.7K | 160,000 | — | ↗ |
| 2023-08-14 | Daly James M | Director | S-Sale | D | Common Stock | 10,000 | 43.74 | 437.4K | 20,503 | — | ↗ |
| 2023-08-11 | Daly James M | Director | S-Sale | D | Common Stock | 10,000 | 43.71 | 437.1K | 30,503 | — | ↗ |
| 2023-07-27 | Torley Helen | Director / Officer | M-Exempt | A | Common Stock | 10,000 | 13.87 | 138.7K | 633,666 | — | ↗ |
| 2023-07-26 | Torley Helen | Director / Officer | S-Sale | D | Common Stock | 10,000 | 42.69 | 426.9K | 623,666 | — | ↗ |
| 2023-07-25 | Torley Helen | Director / Officer | S-Sale | D | Common Stock | 10,000 | 42.80 | 428.0K | 623,666 | — | ↗ |
| 2023-07-18 | LaBarre Michael J. | Officer | S-Sale | D | Common Stock | 10,000 | 40.43 | 404.3K | 141,911 | — | ↗ |
| 2023-06-21 | LaBarre Michael J. | Officer | M-Exempt | A | Common Stock | 10,000 | 18.41 | 184.1K | 151,911 | — | ↗ |
| 2023-05-05 | Posard Matthew L. | Director | A-Award | A | Common Stock | 8,065 | 0.00 | — | 113,254 | — | ↗ |
| 2023-05-05 | Miyashita Akiko Moni | Director | A-Award | A | Option to Purchase Common Stock | 11,371 | 31.00 | 352.5K | 11,371 | — | ↗ |
| 2023-05-05 | MATSUI CONNIE | Director | A-Award | A | Common Stock | 8,065 | 0.00 | — | 187,004 | — | ↗ |
| 2023-05-05 | Henderson Jeffrey William | Director | A-Award | A | Option to Purchase Common Stock | 11,371 | 31.00 | 352.5K | 11,371 | — | ↗ |
| 2023-05-05 | Duncan Barbara Gayle | Director | A-Award | A | Option to Purchase Common Stock | 11,371 | 31.00 | 352.5K | 11,371 | — | ↗ |
| 2023-05-05 | Daly James M | Director | A-Award | A | Option to Purchase Common Stock | 11,371 | 31.00 | 352.5K | 11,371 | — | ↗ |
| 2023-05-05 | Connaughton Bernadette | Director | A-Award | A | Option to Purchase Common Stock | 11,371 | 31.00 | 352.5K | 11,371 | — | ↗ |
| 2023-05-05 | BIZZARI JEAN-PIERRE | Director | A-Award | A | Option to Purchase Common Stock | 11,371 | 31.00 | 352.5K | 11,371 | — | ↗ |
| 2023-04-18 | LaBarre Michael J. | Officer | S-Sale | D | Common Stock | 10,000 | 36.00 | 360.0K | 141,911 | — | ↗ |
Executive team
Top executives
EBIT / Employee
2.33M
Shares Outstanding
118.47M
Executive compensation
Executive compensation (annual)
| # | Year | Executive | Salary | Bonus | Stock award | Option award | Incentive | Other | Total | % Stock- based |
Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2025 | Helen I. Torley President and Chief Executive Officer | 1.00M | — | 19.35M | 1.65M | 1.15M | 18.6K | 23.17M | 90.65% | ↗ |
| 2 | 2025 | Nicole LaBrosse Senior Vice President, Chief Financial Officer | 604.2K | — | 2.98M | 525.0K | 462.2K | 12.3K | 4.58M | 76.44% | ↗ |
| 3 | 2025 | Mark Snyder Senior Vice President, General Counsel, Chief Compliance Officer and Corporate Secretary | 619.0K | — | 2.98M | 525.0K | 394.6K | 17.8K | 4.53M | 77.24% | ↗ |
| 4 | 2025 | Cortney Caudill Senior Vice President, Chief Operating Officer | 561.0K | — | 1.74M | 512.5K | 382.5K | 9.2K | 3.20M | 70.25% | ↗ |
| 5 | 2025 | Michael J. LaBarre Former Senior Vice President, Chief Technical Officer | 120.3K | — | 1.57M | 276.5K | — | 90.2K | 2.05M | 89.75% | ↗ |
| 6 | 2024 | Helen I. Torley President and Chief Executive Officer | 960.0K | — | 8.84M | 1.56M | 1.36M | 18.0K | 12.74M | 81.62% | ↗ |
| 7 | 2024 | Mark Snyder Senior Vice President, General Counsel, Chief Compliance Officer and Corporate Secretary | 579.0K | — | 3.76M | 487.5K | 548.2K | 17.6K | 5.39M | 78.78% | ↗ |
| 8 | 2024 | Nicole LaBrosse Senior Vice President, Chief Financial Officer | 568.2K | — | 2.64M | 465.0K | 538.0K | 12.0K | 4.22M | 73.49% | ↗ |
| 9 | 2024 | Michael J. LaBarre Senior Vice President, Chief Technical Officer | 556.2K | — | 1.87M | 330.0K | 263.3K | 18.8K | 3.04M | 72.41% | ↗ |
| 10 | 2024 | Michael J. LaBarre Former Senior Vice President, Chief Technical Officer | 556.2K | — | 1.87M | 330.0K | 263.3K | 18.8K | 3.04M | 72.41% | ↗ |
| 11 | 2023 | Helen I. Torley President and Chief Executive Officer | 920.0K | — | 6.20M | 3.80M | 883.5K | 17.4K | 11.82M | 84.60% | ↗ |
| 12 | 2023 | Nicole LaBrosse Senior Vice President, Chief Financial Officer | 546.2K | — | 1.80M | 1.20M | 291.4K | 11.8K | 3.85M | 77.94% | ↗ |
| 13 | 2023 | Mark Snyder Senior Vice President, General Counsel, Chief Compliance Officer and Corporate Secretary | 546.0K | — | 1.62M | 1.08M | 349.5K | 17.3K | 3.61M | 74.73% | ↗ |
| 14 | 2023 | Michael J. LaBarre Former Senior Vice President, Chief Technical Officer | 538.2K | — | 1.44M | 960.0K | 287.1K | 18.6K | 3.24M | 73.99% | ↗ |
| 15 | 2023 | Michael J. LaBarre Senior Vice President, Chief Technical Officer | 538.2K | — | 1.44M | 960.0K | 287.1K | 18.6K | 3.24M | 73.99% | ↗ |
| 16 | 2022 | Helen I. Torley President and Chief Executive Officer | 871.7K | — | 4.95M | 3.30M | 557.9K | 17.3K | 9.70M | 85.08% | ↗ |
| 17 | 2022 | Mark Snyder Senior Vice President, General Counsel, Chief Compliance Officer and Corporate Secretary | 525.0K | — | 1.75M | 1.25M | 198.5K | 16.7K | 3.74M | 80.21% | ↗ |
| 18 | 2022 | Michael J. LaBarre Senior Vice President, Chief Technical Officer | 520.0K | — | 1.44M | 960.0K | 187.2K | 16.0K | 3.12M | 76.84% | ↗ |
| 19 | 2022 | Nicole LaBrosse Senior Vice President Chief Financial Officer | 467.8K | — | 1.20M | 800.0K | 201.0K | 14.2K | 2.68M | 74.54% | ↗ |
| 20 | 2022 | Nicole LaBrosse Senior Vice President, Chief Financial Officer | 467.8K | — | 1.20M | 800.0K | 201.0K | 14.2K | 2.68M | 74.54% | ↗ |
| 21 | 2022 | Elaine D. Sun Former Senior Vice President Chief Financial Officer | 44.9K | — | — | — | — | 70.8K | 115.7K | 0.00% | ↗ |
| 22 | 2021 | Helen I. Torley President and Chief Executive Officer | 830.2K | — | 4.06M | 1.74M | 807.6K | 15.4K | 7.45M | 77.82% | ↗ |
| 23 | 2021 | Masaru Matsuda Senior Vice President, General Counsel, Chief Compliance Officer and Corporate Secretary | 457.6K | — | 1.05M | 450.0K | 205.9K | 594.5K | 2.76M | 54.39% | ↗ |
| 24 | 2021 | Michael J. LaBarre Senior Vice President, Chief Technical Officer | 494.0K | — | 1.05M | 450.0K | 270.2K | 15.3K | 2.28M | 65.80% | ↗ |
| 25 | 2021 | Elaine D. Sun Senior Vice President Chief Financial Officer | 494.0K | — | 1.16M | 495.0K | — | 14.3K | 2.16M | 76.45% | ↗ |
| 26 | 2021 | Elaine D. Sun Former Senior Vice President Chief Financial Officer | 494.0K | — | 1.16M | 495.0K | — | 14.3K | 2.16M | 76.45% | ↗ |
| 27 | 2020 | Helen I. Torley President and Chief Executive Officer | 791.4K | — | 2.50M | 2.50M | 712.3K | 15.1K | 6.52M | 76.70% | ↗ |
| 28 | 2020 | Elaine D. Sun Former Senior Vice President Chief Financial Officer | 395.8K | 150.0K | 1.50M | 1.00M | 180.4K | 133.4K | 3.36M | 74.42% | ↗ |
| 29 | 2020 | Elaine D. Sun Senior Vice President Chief Financial Officer | 395.8K | 150.0K | 1.50M | 1.00M | 180.4K | 133.4K | 3.36M | 74.42% | ↗ |
| 30 | 2020 | Michael J. LaBarre Senior Vice President, Chief Technical Officer | 475.0K | — | 650.0K | 650.0K | 220.2K | 15.0K | 2.01M | 64.67% | ↗ |
| 31 | 2020 | Masaru Matsuda Senior Vice President, General Counsel, Chief Compliance Officer and Corporate Secretary | 440.0K | 50.0K | 500.0K | 500.0K | 203.9K | 13.9K | 1.71M | 58.55% | ↗ |
| 32 | 2020 | Laurie D. Stelzer Former Senior Vice President, Chief Financial Officer | 93.2K | — | — | — | — | 78.0K | 171.2K | 0.00% | ↗ |
| 33 | 2019 | Helen I. Torley President and Chief Executive Officer | 761.0K | — | 2.18M | 2.18M | 712.3K | 15.6K | 5.86M | 74.58% | ↗ |
| 34 | 2019 | Alison Armour Former Senior Vice President, Head of Research & Development | 324.4K | 200.0K | 1.00M | 1.00M | 152.3K | 2.0K | 2.68M | 74.66% | ↗ |
| 35 | 2019 | Laurie D. Stelzer Former Senior Vice President, Chief Financial Officer | 495.0K | 2.5K | 750.0K | 750.0K | 231.7K | 16.9K | 2.25M | 66.78% | ↗ |
| 36 | 2019 | Benjamin J. Hickey Former Senior Vice President, Chief Commercial Officer | 483.0K | 121.0K | 625.0K | 625.0K | 226.0K | 122.0K | 2.20M | 56.77% | ↗ |
| 37 | 2019 | Harry J. Leonhardt Former Senior Vice President, General Counsel | 464.0K | — | 625.0K | 625.0K | 217.2K | 16.5K | 1.95M | 64.18% | ↗ |
| 38 | 2018 | Helen I. Torley President and Chief Executive Officer | 725.0K | — | 2.12M | 2.12M | 831.7K | 11.7K | 5.80M | 72.96% | ↗ |
| 39 | 2018 | Benjamin J. Hickey Senior Vice President and Chief Commercial Officer | 145.3K | 180.0K | 1.50M | 1.50M | 86.2K | 91.5K | 3.50M | 85.64% | ↗ |
| 40 | 2018 | Benjamin J. Hickey Former Senior Vice President, Chief Commercial Officer | 145.3K | 180.0K | 1.50M | 1.50M | 86.2K | 91.5K | 3.50M | 85.64% | ↗ |
| 41 | 2018 | Laurie D. Stelzer Former Senior Vice President, Chief Financial Officer | 470.0K | — | 575.0K | 575.0K | 323.5K | 9.4K | 1.95M | 58.89% | ↗ |
| 42 | 2018 | Laurie D. Stelzer Senior Vice President and Chief Financial Officer | 470.0K | — | 575.0K | 575.0K | 323.5K | 9.4K | 1.95M | 58.89% | ↗ |
| 43 | 2018 | Harry J. Leonhardt Former Senior Vice President, General Counsel | 442.0K | — | 575.0K | 575.0K | 304.2K | 11.4K | 1.91M | 60.29% | ↗ |
| 44 | 2018 | Harry J. Leonhardt Senior Vice President, General Counsel | 442.0K | — | 575.0K | 575.0K | 304.2K | 11.4K | 1.91M | 60.29% | ↗ |
| 45 | 2018 | Dimitrios Chondros Senior Vice President and Chief Medical Officer | 440.8K | — | 500.0K | 500.0K | 263.8K | 9.3K | 1.71M | 58.35% | ↗ |
| 46 | 2017 | Helen I. Torley President and Chief Executive Officer | 671.0K | — | 1.90M | 1.90M | 699.1K | 10.4K | 5.18M | 73.35% | ↗ |
| 47 | 2017 | Laurie D. Stelzer Senior Vice President and Chief Financial Officer | 452.0K | — | 550.0K | 550.0K | 282.6K | 9.2K | 1.84M | 59.66% | ↗ |
| 48 | 2017 | Laurie D. Stelzer Former Senior Vice President, Chief Financial Officer | 452.0K | — | 550.0K | 550.0K | 282.6K | 9.2K | 1.84M | 59.66% | ↗ |
| 49 | 2017 | Harry J. Leonhardt Senior Vice President, General Counsel, Chief Compliance Officer and Corporate Secretary | 425.0K | — | 550.0K | 550.0K | 242.6K | 11.1K | 1.78M | 61.84% | ↗ |
| 50 | 2017 | Harry J. Leonhardt Senior Vice President, General Counsel | 425.0K | — | 550.0K | 550.0K | 242.6K | 11.1K | 1.78M | 61.84% | ↗ |
| 51 | 2017 | Harry J. Leonhardt Former Senior Vice President, General Counsel | 425.0K | — | 550.0K | 550.0K | 242.6K | 11.1K | 1.78M | 61.84% | ↗ |
| 52 | 2017 | Athena M. Countouriotis Former Senior Vice President and Chief Medical Officer | 236.5K | — | 550.0K | 550.0K | — | 323.8K | 1.66M | 66.25% | ↗ |
| 53 | 2017 | Mark J. Gergen Former Senior Vice President and Chief Operating Officer | 365.6K | — | 550.0K | 550.0K | — | 147.0K | 1.61M | 68.21% | ↗ |
| 54 | 2016 | Helen I. Torley President and Chief Executive Officer | 645.0K | — | 1.80M | 1.80M | 595.4K | 9.6K | 4.85M | 74.23% | ↗ |
| 55 | 2016 | Mark J. Gergen Senior Vice President and Chief Operating Officer | 145.0K | — | — | 2.00M | 75.0K | 2.5K | 2.22M | 90.00% | ↗ |
| 56 | 2016 | Mark J. Gergen Former Senior Vice President and Chief Operating Officer | 145.0K | — | — | 2.00M | 75.0K | 2.5K | 2.22M | 90.00% | ↗ |
| 57 | 2016 | Laurie D. Stelzer Senior Vice President and Chief Financial Officer | 435.0K | — | 750.0K | 500.0K | 207.0K | 8.6K | 1.90M | 65.77% | ↗ |
| 58 | 2016 | Athena M. Countouriotis Senior Vice President and Chief Medical Officer | 443.0K | — | 600.0K | 600.0K | 200.0K | 8.7K | 1.85M | 64.81% | ↗ |
| 59 | 2016 | Athena M. Countouriotis Former Senior Vice President and Chief Medical Officer | 443.0K | — | 600.0K | 600.0K | 200.0K | 8.7K | 1.85M | 64.81% | ↗ |
| 60 | 2016 | Harry J. Leonhardt Senior Vice President, General Counsel | 405.0K | — | 500.0K | 500.0K | 204.0K | 10.8K | 1.62M | 61.74% | ↗ |
| 61 | 2016 | Harry J. Leonhardt Senior Vice President, General Counsel, Chief Compliance Officer and Corporate Secretary | 405.0K | — | 500.0K | 500.0K | 204.0K | 10.8K | 1.62M | 61.74% | ↗ |
| 62 | 2015 | Helen I. Torley President and Chief Executive Officer | 624.0K | — | 1.73M | 1.63M | 616.4K | 9.1K | 4.62M | 72.94% | ↗ |
| 63 | 2015 | Laurie D. Stelzer Senior Vice President and Chief Financial Officer | 229.1K | — | 561.8K | 2.73M | 125.0K | 200.3K | 3.84M | 85.57% | ↗ |
| 64 | 2015 | Harry J. Leonhardt Senior Vice President, General Counsel, Chief Compliance Officer and Corporate Secretary | 262.2K | — | 429.8K | 2.07M | 145.0K | 8.4K | 2.92M | 85.75% | ↗ |
| 65 | 2015 | Athena M. Countouriotis Former Senior Vice President and Chief Medical Officer | 427.0K | 300.0K | 299.7K | 1.47M | 202.0K | 7.6K | 2.70M | 65.33% | ↗ |
| 66 | 2015 | Athena M. Countouriotis Senior Vice President and Chief Medical Officer | 427.0K | 300.0K | 299.7K | 1.47M | 202.0K | 7.6K | 2.70M | 65.33% | ↗ |
| 67 | 2015 | David A. Ramsay Vice President and Chief Financial Officer | 254.0K | — | 386.7K | 364.8K | — | 8.5K | 1.01M | 74.12% | ↗ |
| 68 | 2014 | Helen I. Torley President and Chief Executive Officer | 593.4K | 1.00M | 1.76M | 6.44M | 382.5K | 227.9K | 10.40M | 78.81% | ↗ |
| 69 | 2014 | David A. Ramsay Vice President and Chief Financial Officer | 364.9K | — | 371.4K | 367.2K | 129.9K | 8.7K | 1.24M | 59.47% | ↗ |
| 70 | 2014 | 2014 SUMMARY COMPENSATION TABLE Name and Principal Position | 2.0K | 2.0K | 2.0K | 2.0K | 2.0K | 2.0K | 2.0K | 200.00% | ↗ |
| 71 | 2014 | David A. Ramsay Vice President and Chief Financial Officer | — | — | — | — | — | — | — | — | ↗ |
| 72 | 2014 | Gregory I. Frost Former President and Chief Executive Officer | — | — | — | — | — | — | — | — | ↗ |
| 73 | 2014 | Jean I. Liu Former Vice President, General Counsel and Secretary | — | — | — | — | — | — | — | — | ↗ |
| 74 | 2014 | James P. Shaffer Former Vice President and Chief Commercial Officer | — | — | — | — | — | — | — | — | ↗ |
| 75 | 2013 | David A. Ramsay Vice President and Chief Financial Officer | 314.9K | — | 563.5K | 593.2K | 201.4K | 8.1K | 1.68M | 68.80% | ↗ |
| 76 | 2013 | 2013 SUMMARY COMPENSATION TABLE Name and Principal Position | 2.0K | — | 2.0K | 2.0K | 2.0K | 2.0K | 2.0K | 200.00% | ↗ |
| 77 | 2013 | Gregory I. Frost Former President and Chief Executive Officer | — | — | — | — | — | — | — | — | ↗ |
| 78 | 2013 | Kurt A. Gustafson Former Vice President and Chief Financial Officer | — | — | — | — | — | — | — | — | ↗ |
| 79 | 2013 | Jean I. Liu Former Vice President, General Counsel and Secretary | — | — | — | — | — | — | — | — | ↗ |
| 80 | 2013 | James P. Shaffer Vice President and Chief Commercial Officer | — | — | — | — | — | — | — | — | ↗ |
| 81 | 2013 | H. Michael Shepard Vice President and Chief Scientific Officer | — | — | — | — | — | — | — | — | ↗ |
| 82 | 2013 | David A. Ramsay Vice President and Chief Financial Officer | — | — | — | — | — | — | — | — | ↗ |
| 83 | 2013 | Jean I. Liu Vice President, General Counsel and Secretary | — | — | — | — | — | — | — | — | ↗ |
| 84 | 2013 | James P. Shaffer Former Vice President and Chief Commercial Officer | — | — | — | — | — | — | — | — | ↗ |
| 85 | 2012 | 2012 SUMMARY COMPENSATION TABLE Name and Principal Position | 2.0K | — | 2.0K | 2.0K | 2.0K | 2.0K | 2.0K | 200.00% | ↗ |
| 86 | 2012 | Jean I. Liu Former Vice President, General Counsel and Secretary | — | — | — | — | — | — | — | — | ↗ |
| 87 | 2012 | Kurt A. Gustafson Vice President and Chief Financial Officer | — | — | — | — | — | — | — | — | ↗ |
| 88 | 2012 | H. Michael Shepard Vice President and Chief Scientific Officer | — | — | — | — | — | — | — | — | ↗ |
| 89 | 2012 | David A. Ramsay Vice President and Chief Financial Officer | — | — | — | — | — | — | — | — | ↗ |
| 90 | 2012 | Gregory I. Frost President and Chief Executive Officer | — | — | — | — | — | — | — | — | ↗ |
| 91 | 2012 | Kurt A. Gustafson Former Vice President and Chief Financial Officer | — | — | — | — | — | — | — | — | ↗ |
| 92 | 2012 | James P. Shaffer Former Vice President and Chief Commercial Officer | — | — | — | — | — | — | — | — | ↗ |
| 93 | 2012 | James P. Shaffer Vice President and Chief Commercial Officer | — | — | — | — | — | — | — | — | ↗ |
| 94 | 2012 | Gregory I. Frost Former President and Chief Executive Officer | — | — | — | — | — | — | — | — | ↗ |
| 95 | 2012 | Jean I. Liu Vice President, General Counsel and Secretary | — | — | — | — | — | — | — | — | ↗ |
| 96 | 2011 | James P. Shaffer Vice President and Chief Commercial Officer | 120.7K | — | — | 982.9K | 35.0K | 16.2K | 1.15M | 85.12% | ↗ |
| 97 | 2011 | Jean . Liu Vice President, General Counsel and Secretary | 50.0K | — | — | 982.9K | — | 14.6K | 1.05M | 93.83% | ↗ |
| 98 | 2011 | William J. Fallon Vice President, Manufacturing Operations | 312.6K | — | 126.7K | 170.8K | 90.0K | 8.7K | 708.8K | 41.98% | ↗ |
| 99 | 2011 | David A. Ramsay Vice President and Chief Financial Officer | — | — | — | — | — | — | — | — | ↗ |
| 100 | 2011 | Gregory I. Frost President and Chief Executive Officer | — | — | — | — | — | — | — | — | ↗ |
| 101 | 2011 | Kurt A. Gustafson Vice President and Chief Financial Officer | — | — | — | — | — | — | — | — | ↗ |
| 102 | 2011 | Kurt A. Gustafson Former Vice President and Chief Financial Officer | — | — | — | — | — | — | — | — | ↗ |
| 103 | 2011 | Jean I. Liu Vice President, General Counsel and Secretary | — | — | — | — | — | — | — | — | ↗ |
| 104 | 2011 | Gregory I. Frost Former President and Chief Executive Officer | — | — | — | — | — | — | — | — | ↗ |
| 105 | 2011 | James P. Shaffer Vice President and Chief Commercial Officer | — | — | — | — | — | — | — | — | ↗ |
| 106 | 2011 | H. Michael Shepard Vice President and Chief Scientific Officer | — | — | — | — | — | — | — | — | ↗ |
| 107 | 2010 | Jonathan E. Lim Former President and Chief Executive Officer | 383.6K | — | — | — | — | 490.6K | 1.29M | 0.00% | ↗ |
| 108 | 2010 | Robert L. Little Vice President and Chief Commercial Officer | 318.0K | — | — | — | — | 207.4K | 623.5K | 0.00% | ↗ |
| 109 | 2010 | Jonathan A. Leff Vice President and Chief Medical Officer | 315.1K | — | — | — | — | 253.6K | 568.7K | 0.00% | ↗ |
| 110 | 2010 | William J. Fallon Vice President, Manufacturing Operations | 302.0K | — | — | 140.2K | 76.8K | 8.0K | 527.1K | 26.60% | ↗ |
| 111 | 2010 | Kurt A. Gustafson Vice President, Secretary and Chief Financial Officer | 310.0K | — | — | — | 78.9K | 7.7K | 489.8K | 0.00% | ↗ |
| 112 | 2010 | Michael J. LaBarre Vice President, Product Development | 248.6K | — | — | — | 63.3K | 7.7K | 437.9K | 0.00% | ↗ |
| 113 | 2010 | Gregory I. Frost President and Chief Executive Officer | — | — | — | — | — | — | — | — | ↗ |
| 114 | 2010 | Kurt A. Gustafson Vice President and Chief Financial Officer | — | — | — | — | — | — | — | — | ↗ |
| 115 | 2010 | H. Michael Shepard Vice President and Chief Scientific Officer | — | — | — | — | — | — | — | — | ↗ |
| 116 | 2009 | Jonathan A. Leff Vice President and Chief Medical Officer | 177.5K | 25.0K | — | — | 4.0K | 5.0K | 1.09M | 0.00% | ↗ |
| 117 | 2009 | Kurt A. Gustafson Vice President and Chief Financial Officer | 225.0K | — | — | 681.9K | 4.9K | 148.6K | 1.06M | 64.31% | ↗ |
| 118 | 2009 | Kurt A. Gustafson Vice President, Secretary and Chief Financial Officer | 225.0K | — | — | — | 4.9K | 148.6K | 1.06M | 0.00% | ↗ |
| 119 | 2009 | Jonathan E. Lim Former President and Chief Executive Officer | 395.0K | — | — | — | 12.1K | 7.7K | 837.0K | 0.00% | ↗ |
| 120 | 2009 | H. Michael Shepard Vice President and Chief Scientific Officer | 152.7K | — | — | 557.4K | 32.6K | 60.1K | 802.8K | 69.43% | ↗ |
| 121 | 2009 | Gregory I. Frost President and Chief Executive Officer | 375.0K | — | — | 281.5K | 8.6K | 7.7K | 672.8K | 41.84% | ↗ |
| 122 | 2009 | William J. Fallon Vice President, Manufacturing Operations | 287.0K | — | — | 140.8K | 6.6K | 8.0K | 442.3K | 31.82% | ↗ |
| 123 | 2009 | Robert L. Little Vice President and Chief Commercial Officer | 334.0K | — | — | — | 5.4K | 2.2K | 412.0K | 0.00% | ↗ |
| 124 | 2009 | Michael J. LaBarre Vice President, Product Development | 241.4K | — | — | — | 63.4K | 7.4K | 361.6K | 0.00% | ↗ |
| 125 | 2009 | Gregory I. Frost Vice President and Chief Scientific Officer | — | — | — | — | — | — | — | — | ↗ |
| 126 | 2009 | David A. Ramsay Vice President — Corporate Development | — | — | — | — | — | — | — | — | ↗ |
| 127 | 2009 | Jonathan A. Leff | — | — | — | — | — | — | — | — | ↗ |
| 128 | 2009 | Jonathan E. Lim President and Chief Executive Officer | — | — | — | — | — | — | — | — | ↗ |
| 129 | 2009 | Kurt A. Gustafson | — | — | — | — | — | — | — | — | ↗ |
| 130 | 2008 | Jonathan E. Lim Former President and Chief Executive Officer | 375.0K | — | — | — | — | 468.00 | 539.9K | 0.00% | ↗ |
| 131 | 2008 | Gregory I. Frost President and Chief Executive Officer | 323.0K | — | — | — | — | 393.00 | 487.8K | 0.00% | ↗ |
| 132 | 2008 | Michael J. LaBarre Vice President, Product Development | 127.3K | — | — | — | 31.9K | 133.00 | 474.3K | 0.00% | ↗ |
| 133 | 2008 | Robert L. Little Vice President and Chief Commercial Officer | 322.0K | — | — | — | — | 392.00 | 417.1K | 0.00% | ↗ |
| 134 | 2008 | Richard C. Yocum Vice President — Clinical Development and Medical Affairs | 300.0K | — | — | — | — | 360.00 | 406.3K | 0.00% | ↗ |
| 135 | 2008 | David A. Ramsay Vice President and Chief Financial Officer | 260.0K | — | — | — | — | 302.00 | 370.8K | 0.00% | ↗ |
| 136 | 2008 | William J. Fallon Vice President, Manufacturing Operations | 270.0K | — | — | — | — | 317.00 | 365.0K | 0.00% | ↗ |
| 137 | 2008 | William J. Fallon Vice President — Manufacturing and Operations | 270.0K | — | — | — | — | 317.00 | 354.3K | 0.00% | ↗ |
| 138 | 2008 | Jonathan E. Lim President and Chief Executive Officer | — | — | — | — | — | — | — | — | ↗ |
| 139 | 2008 | Gregory I. Frost Vice President and Chief Scientific Officer | — | — | — | — | — | — | — | — | ↗ |
| 140 | 2008 | David A. Ramsay Vice President — Corporate Development | — | — | — | — | — | — | — | — | ↗ |
| 141 | 2007 | William J. Fallon Vice President — Manufacturing and Operations | 255.0K | 20.0K | — | — | 66.9K | 136.4K | 541.0K | 0.00% | ↗ |
| 142 | 2007 | Richard C. Yocum Vice President — Clinical Development and Medical Affairs | 268.5K | — | — | — | 70.9K | 306.00 | 420.7K | 0.00% | ↗ |
| 143 | 2007 | David A. Ramsay Vice President and Chief Financial Officer | 231.3K | — | — | — | 54.6K | 247.00 | 356.5K | 0.00% | ↗ |
| 144 | 2007 | David A. Ramsay Vice President — Corporate Development | — | — | — | — | — | — | — | — | ↗ |
| 145 | 2007 | Jonathan E. Lim President and Chief Executive Officer | — | — | — | — | — | — | — | — | ↗ |
| 146 | 2007 | Robert L. Little Vice President and Chief Commercial Officer | — | — | — | — | — | — | — | — | ↗ |
| 147 | 2007 | Gregory I. Frost Vice President and Chief Scientific Officer | — | — | — | — | — | — | — | — | ↗ |
| 148 | 2006 | Jonathan E. Lim President and Chief Executive Officer | 300.0K | — | — | — | 53.6K | 246.00 | 428.1K | 0.00% | ↗ |
| 149 | 2006 | Gregory I. Frost Vice President and Chief Scientific Officer | 210.0K | — | — | — | 31.5K | 188.00 | 335.5K | 0.00% | ↗ |
| 150 | 2006 | Richard C. Yocum Vice President — Clinical Development and Medical Affairs | 240.0K | — | — | — | 36.0K | 232.00 | 333.2K | 0.00% | ↗ |
| 151 | 2006 | David A. Ramsay Vice President and Chief Financial Officer | 180.0K | — | — | — | 25.7K | 162.00 | 266.8K | 0.00% | ↗ |
| 152 | 2006 | Robert L. Little Vice President and Chief Commercial Officer | 144.1K | — | — | — | 21.8K | 120.00 | 195.6K | 0.00% | ↗ |
| 153 | 2006 | William J. Fallon Vice President — Manufacturing and Operations | 39.7K | — | — | — | — | 14.4K | 63.0K | 0.00% | ↗ |
| 154 | 2006 | Gregory I. Frost Chief Scientific Officer | — | — | — | — | — | — | — | — | ↗ |
| 155 | 2006 | Don A. Kennard Vice President of Regulatory Affairs and Quality | — | — | — | — | — | — | — | — | ↗ |
| 156 | 2006 | Richard C. Yocum Vice President of Clinical | — | — | — | — | — | — | — | — | ↗ |
| 157 | 2005 | Jonathan E. Lim President and Chief Executive Officer | 200.0K | — | — | — | 70.0K | 90.00 | 448.7K | 0.00% | ↗ |
| 158 | 2005 | Gregory I. Frost Vice President and Chief Scientific Officer | 160.0K | — | — | — | 50.0K | 66.00 | 302.0K | 0.00% | ↗ |
| 159 | 2005 | David A. Ramsay Vice President and Chief Financial Officer | 150.0K | — | — | — | 50.0K | 60.00 | 260.0K | 0.00% | ↗ |
| 160 | 2005 | Richard C. Yocum Vice President — Clinical Development and Medical Affairs | 140.4K | — | — | — | 37.5K | 84.00 | 220.5K | 0.00% | ↗ |
| 161 | 2005 | Don A. Kennard Vice President of Regulatory Affairs | 150.0K | 50.0K | — | — | — | — | 200.0K | 0.00% | ↗ |
| 162 | 2005 | Carolyn M. Rynard Vice President of Product Development and Manufacturing | 140.0K | 40.0K | — | — | — | — | 180.0K | 0.00% | ↗ |
| 163 | 2005 | Gregory I. Frost Chief Scientific Officer | — | — | — | — | — | — | — | — | ↗ |
| 164 | 2005 | Richard C. Yocum Vice President of Clinical | — | — | — | — | — | — | — | — | ↗ |
| 165 | 2005 | Don A. Kennard Vice President of Regulatory Affairs and Quality | — | — | — | — | — | — | — | — | ↗ |
| 166 | 2004 | Gregory I. Frost Chief Scientific Officer | 153.4K | — | — | — | — | — | 153.4K | 0.00% | ↗ |
| 167 | 2004 | David A. Ramsay Chief Financial Officer | 138.9K | — | — | — | — | — | 138.9K | 0.00% | ↗ |
| 168 | 2004 | Carolyn Rynard Vice President, Product Development | 120.2K | — | — | — | — | — | 120.2K | 0.00% | ↗ |
| 169 | 2004 | Carolyn M. Rynard Vice President of Product Development and Manufacturing | 120.2K | — | — | — | — | — | 120.2K | 0.00% | ↗ |
| 170 | 2004 | Mark Wilson Vice President, Business Development | 120.2K | — | — | — | — | — | 120.2K | 0.00% | ↗ |
| 171 | 2004 | Don A. Kennard Vice President of Regulatory Affairs | 118.5K | — | — | — | — | — | 118.5K | 0.00% | ↗ |
| 172 | 2004 | Don A. Kennard Vice President of Regulatory Affairs and Quality | — | — | — | — | — | — | — | — | ↗ |
| 173 | 2004 | David A. Ramsay Vice President and Chief Financial Officer | — | — | — | — | — | — | — | — | ↗ |
| 174 | 2004 | Jonathan E. Lim President and Chief Executive Officer | — | — | — | — | — | — | — | — | ↗ |
| 175 | 2003 | Gregory I. Frost Chief Scientific Officer | 92.5K | — | — | — | — | — | 92.5K | 0.00% | ↗ |
| 176 | 2003 | Jonathan E. Lim President and Chief Executive Officer | 66.7K | — | — | — | — | — | 66.7K | 0.00% | ↗ |
| 177 | 2003 | Mark Wilson Vice President, Business Development | 36.7K | — | — | — | — | — | 36.7K | 0.00% | ↗ |
| 178 | 2003 | Carolyn Rynard Vice President, Product Development | 17.7K | — | — | — | — | — | 17.7K | 0.00% | ↗ |
| 179 | 2003 | Carolyn M. Rynard Vice President of Product Development and Manufacturing | 17.7K | — | — | — | — | — | 17.7K | 0.00% | ↗ |
| 180 | 2003 | David A. Ramsay Chief Financial Officer | 12.2K | — | — | — | — | — | 12.2K | 0.00% | ↗ |
| 181 | 2003 | David A. Ramsay Vice President and Chief Financial Officer | 12.2K | — | — | — | — | — | 12.2K | 0.00% | ↗ |
CEO compensation breakdown
Proxy statements
Proxy statements (DEF 14A)
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Helen I. Torley | President, Chief Executive Officer & Director | 2M | — |
| Nicole LaBrosse | Senior Vice President & Chief Financial Officer | 1M | female |
| Mark Snyder | Senior Vice President, General Counsel, Chief Compliance Officer & nd Secretary | 1M | male |
| Cortney Caudill | Senior Vice President & Chief Operating Officer | 952.7K | female |
| David A. Ramsay | Interim Chief Financial Officer | 262.5K | male |
| Charles Theuer | Chief Medical Officer | — | — |
| Tram Bui | Head of Investor Relations & Corporate Communications | — | female |
| Chase Coffman | President of Hypercon | — | male |
| Christopher Wahl | Chief Scientific Officer | — | — |
| Paul Spence | Chief Commercial Officer | — | male |
| Rhys de Callier | Chief Strategy Officer | — | male |
ESG Rating
ESG Score History BIOTECHNOLOGY
Benchmark vs Sector
Political Trading Activity (25M)
Senate Trading Activity
| Transaction Date | Disclosed | Senator | State | Owner | Type | Amount | Link |
|---|---|---|---|---|---|---|---|
| 2017-11-06 | 2017-12-08 | Mark Warner | VA | Self | Sale (Full) | $500,001 - $1,000,000 | ↗ |
House Trading Activity
| Transaction Date | Disclosed | Representative | District | Owner | Type | Amount | Link |
|---|---|---|---|---|---|---|---|
| 2025-03-24 | 2025-04-07 | Gilbert Cisneros | CA31 | — | Sale (Partial) | $1,001 - $15,000 | ↗ |
| 2024-09-09 | 2024-10-03 | Josh Gottheimer | NJ05 | Joint | Sale (Partial) | $1,001 - $15,000 | ↗ |
| 2023-07-12 | 2023-08-13 | Daniel Goldman | NY10 | — | Sale | $15,001 - $50,000 | ↗ |
| 2022-12-06 | 2023-01-13 | Josh Gottheimer | NJ05 | Joint | Sale (Partial) | $1,001 - $15,000 | ↗ |
| 2020-10-22 | 2020-11-05 | Gilbert Cisneros | CA31 | — | Purchase | $1,001 - $15,000 | ↗ |
| 2020-10-19 | 2020-11-05 | Josh Gottheimer | NJ05 | Joint | Purchase | $1,001 - $15,000 | ↗ |
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for HALO
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
